Effect of Metabolic Disease and Xenobiotic Exposure on Hepatic ATP-Binding Cassette (ABC) Drug Transporter Expression by Donepudi, Ajay Chowdary
University of Rhode Island 
DigitalCommons@URI 
Open Access Dissertations 
2013 
Effect of Metabolic Disease and Xenobiotic Exposure on Hepatic 
ATP-Binding Cassette (ABC) Drug Transporter Expression 
Ajay Chowdary Donepudi 
University of Rhode Island, ajaydonepudi@gmail.com 
Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss 
Recommended Citation 
Donepudi, Ajay Chowdary, "Effect of Metabolic Disease and Xenobiotic Exposure on Hepatic ATP-Binding 
Cassette (ABC) Drug Transporter Expression" (2013). Open Access Dissertations. Paper 39. 
https://digitalcommons.uri.edu/oa_diss/39 
This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for 
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more 
information, please contact digitalcommons@etal.uri.edu. 
EFFECT OF METABOLIC DISEASE AND XENOBIOTIC EXPOSURE ON 
HEPATIC ATP-BINDING CASSETTE (ABC) DRUG TRANSPORTER 
EXPRESSION  
 
BY 
 
AJAY CHOWDARY DONEPUDI 
 
 
A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE  
REQUIREMENTS FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
IN 
PHARMACOLOGY AND TOXICOLOGY 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
 
2013 
 
 
 
DOCTOR OF PHILOSOPHY DISSERTATION 
 
OF 
 
AJAY CHOWDARY DONEPUDI 
 
 
 
 
 
 
 
 
              APPROVED:  
 
                   Dissertation Committee: 
 
                           Major Professor Angela L. Slitt 
      Nasser H. Zawia 
      Jeffrey Moffit 
      Ingrid Lofgren 
      Nasser H. Zawia  
DEAN OF THE GRADUATE SCHOOL 
 
 
UNIVERSITY OF RHODE ISLAND 
2013
ABSTRACT 
Drug transporters are membrane bound proteins, which are involved in 
facilitating both uptake and efflux of xenobiotics, endogenous compounds and 
their metabolites in various tissues such as liver, kidney, testis, and brain.  
Alteration in drug transporters may cause imbalances in endogenous 
compounds such as bile acids, hormones, and bilirubin.  Xenobiotic 
metabolism is inefficient without drug transporters, and drug transporters are 
recognized as vital mediators for moving polar compounds across 
membranes.  ATP binding cassette (Abc) transporters are a kind of drug 
transporters, which are ATP-dependent membrane bound proteins involved in 
transport of wide variety of compounds.   Multiple hepatic conditions can alter 
drug transporter expression such as obesity, oxidative stress, cytokines, drug-
induced liver injury and environmental toxicants.  Specifically, drug transporter 
expression is known to alter during several metabolic conditions.  For 
example, both genetically modified and diet-induced obesity models of rodents 
displayed altered hepatic drug transporter expression.  Previous studies 
shown not only during metabolic syndrome, but also exposure to xenobiotics 
such as estradiol and polybrominated diphenyls (PBDs), which are endocrine 
disrupting chemicals, alter drug transporter expression.  The objective of this 
study is to determine whether certain liver conditions, such as development of 
fatty liver (i.e. steatosis) and developmental exposure to an environmental 
endocrine disruptor (i.e. Bisphenol A) alter hepatic Abc drug transporter 
expression in conjunction with nuclear receptor expression.  This study also 
aims to show, changes in hepatic Phase II and Abc drug transporter 
expression during metabolic syndrome alters metabolism and disposition of 
endocrine disruptor such as Bisphenol A (BPA) This research will provide 
novel observation and mechanisms by which expression of drug transporters 
will be affected and regulated.  To delineate these aspects whole thesis 
research was divided into three specific sub studies: 
 In the first study, which is presented as Manuscript I shows changes 
in hepatic Abc drug transporters, uptake transporters, Phase I enzyme 
expression, and factor involved in regulation of hepatic Abc transporter 
expression during development of obesity.  This study also shows possible 
physiological and transcription factors role in regulation of hepatic Abc 
transporter expression during development of obesity.  In this study, hepatic 
gene expression and physiological factors were analyzed in both C57BL/6 and 
ob/ob mice at different time points such as week-1, 3, 4 and 8 age to capture 
physiological and gene expression changes that occur during development of 
obesity.  Correlation between physiological changes and gene expression was 
performed using canonical correlations.  Significant correlations were 
observed between physiological changes, hormones, and gene expression 
changes during development of obesity. Correlation between metabolism-
related hormones and hepatic gene expression are sex-dependent.  
Correlation between physiological changes and gene expression indicated 
metabolism-related hormones might have a role in regulation of hepatic genes 
involved in drug metabolism and transport.  
In second study, which is presented as Manuscript II shows changes 
in hepatic Abc transporter expression with developmental exposure to 
endocrine disruptor BPA and identifies mechanistic pathways by which BPA 
exposure causes these effects.  In this study, female mice are exposed to 
either control or BPA or ethinyl estradiol (EE) or phytoestrogen enriched diet. 
Studies were performed in male pups to analyze gene expression and 
functional activities of respective genes.  Developmental exposure to BPA and 
EE downregulated hepatic drug transporters and Phase II enzyme expression 
and activity that are involved in BPA metabolism and excretion, whereas 
genistein co-administration reversed these changes.  Changes observed with 
developmental exposure of BPA were persistently observed even after 
cessation of BPA exposure to male pups.  Decrease in nuclear factors mRNA 
expression and binding activity could be partially responsible for 
downregulation of hepatic Phase II enzymes and drug transporter expression.  
Further, increase in expression of histone deactylases (Hdac’s) upon BPA 
exposure could be responsible for decreased transcription factor expression 
and activity.  Our data suggest that developmental BPA and EE exposure may 
work via similar pathways, and greatly affect the expression of key hepatic 
genes involved in BPA and hormone metabolism and clearance.  
In third study, presented as Manuscript III shows changes in hepatic 
drug metabolism gene expression observed during obesity alters BPA, an 
endocrine disruptor disposition.  This study aim to identify whether changes in 
Phase II and drug transporter expression alters BPA disposition, as increase 
in urinary total BPA levels and BPA exposure in humans are correlated to 
occurrence of obesity.  BPA (10 mg/kg, i.v.) was administered; parent and its 
metabolites were analyzed in bile, plasma and urine sample of lean and obese 
rats.  Along with in vivo BPA disposition studies, hepatic glucuronidation and 
sulfation enzymatic assays were performed to identify whether obesity altered 
hepatic metabolic processes.  Changes in hepatic Phase II and III protein 
expression in obese rats resulted in altered BPA metabolism and disposition.  
In obese rats, BPA metabolites specifically BPA-glucuronide levels were 
increased in urine and decreased in bile compared to lean rats.  This altered 
BPA metabolism and disposition during obesity suggests, in humans detailed 
evaluation of urinary BPA levels such as ratio of metabolite to parent 
compound, are needed to correlate BPA exposure to occurrence of obesity. 
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PREFACE 
 
 
This dissertation has been written in the manuscript format as directed by the 
guidelines set by the Graduate School at the University of Rhode Island.  Each 
manuscript follows the format of the journal “Drug Metabolism and 
Disposition”.   
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INTRODUCTION 
1. ATP Binding cassette (Abc) drug transporters: 
The liver is the major organ for metabolism and clearance; it plays a 
predominant role in determining the circulating systemic concentrations of 
many endocrine hormones in the body.  In general, the metabolism of 
endogenous chemicals and xenobiotics involves Phase-I, -II and -III (drug 
transporters) proteins (Figure 1).  Drug transporters are membrane bound 
proteins, which are involved in facilitating both uptake and efflux of 
xenobiotics, endogenous compounds and their metabolites in various tissues 
such as liver, kidney, testis, and brain.  Alteration in drug transporters may 
cause imbalances in endogenous compounds such as bile acids, hormones, 
and bilirubin.  Xenobiotic metabolism is inefficient without drug transporters, 
and drug transporters are recognized as vital mediators for moving polar 
compounds across membranes.  ATP binding cassette (Abc) transporters are 
a kind of drug transporters, which are ATP-dependent membrane-bound 
proteins involved in transport of wide variety of compounds.   Multiple hepatic 
conditions can alter drug transporter expression such as obesity, oxidative 
stress, cytokines, drug-induced liver injury and environmental toxicants.  Drug 
transporters are involved in several critical liver functions such as absorption 
and excretion, which determines the distribution and hepatic concentrations of 
endogenous compounds in the body. Changes in drug transporter expression, 
especially ABC transporters, can cause imbalances in homeostasis of 
endogenous compounds in body, which may lead to several pathological 
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conditions, such as cholestasis, hyperbilirubinemia, drug-induced liver injury 
(Faber et al., 2003; Geier et al., 2003; Aleksunes et al., 2008; Lecureux et al., 
2009).  Impairment of drug transporters causes several pathological conditions 
such as cholestasis and hyperbilirubinemia.  Mice lacking certain drug 
transporters, such as Abcc4, are more susceptible for liver injury during certain 
pathological conditions, such as cholestasis.  ABC transporters have seven 
subfamilies from A to G such as ABCA, ABCB, ABCC, ABCD, ABCE, ABCF 
and ABCG (Dean et al., 2001).  ABC transporters are primarily involved in 
efflux of endogenous and exogenous compounds. 
Figure 1 Depiction xenobiotic and endogenous compounds metabolism 
in liver.  
In liver, ABC drug transporters are important in maintaining the bile acid pool, 
fatty acids, and cholesterol transport and efflux of xenobiotic metabolites.  
Drug transporters in liver are regulated by several nuclear receptors and 
transcription factors such as nuclear factor-E2- related factor 2 (Nrf2), aryl 
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hydrocarbon receptor (Ahr), constitutive androstane receptor (Car), estrogen 
receptor (Er), and Peroxisome proliferator-activated receptor alpha (Ppar-α) 
(Faber et al., 2003; Geier et al., 2003; Maher et al., 2005a). Activation of 
nuclear hormones via pharmacological means or genetic manipulation often 
upregulates drug Abcc transporter expression in liver (Faber et al., 2003; 
Maher et al., 2005a).  
For example, microsomal enzyme inducers, such as [2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated biphenyl 126 (PCB126), 
and beta-naphthoflavone], 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene 
(TCPOBOP) increased Abcc2 expression in mouse liver (Maher et al., 2005a).  
Certain exposures can down-regulate Abcc transporter expression in liver, 
such as lipopolysaccharide (LPS) administration.  Studies mentioned above 
are adulthood exposure studies, only very few studies describe whether 
transporters and hepatic clearance mechanisms are regulated by early in life 
exposure that can contribute to epigenetic mechanisms.  
Drug transporters and Phase-II enzyme expression in liver differs from 
neonates to adults in rodent and humans (Coughtrie et al., 1988; Cui et al., 
2010).  In rodents, Abcc transporter expression change with age (Maher et al., 
2005b; Cheng et al., 2007).  In neonates and children, Phase II enzymes such 
as UGTs expression is low compared to adults (Coughtrie et al., 1988). 
Similarly drug transporters such as Abcc family transporters, have low hepatic 
expression in neonates compared to adult mice (Maher et al., 2005b).  In 
rodents, gender dependent Abc transporter expression is observed in liver.  
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For example, Abcc4 is highly expressed in females compared to males (Maher 
et al., 2005b).  In rats, age dependent differences in Phase-II and drug 
transporter expression in neonates are taught to be responsible for cardiac 
glycoside induced toxicity (Guo et al., 2002; Maher et al., 2005b). Low 
expression of hepatic Abcc2 was taught to be one of the reasons for 
occurrence of neonatal jaundice (Maher et al., 2005b). 
2. Obesity: 
Obesity is metabolic disease characterized with increased body mass index 
(BMI≥30) (2010). Obesity is a hallmark disease of metabolic syndrome and 
widely considered as a complex condition. There is growing concerns of 
obesity affecting people worldwide and approximately above 30% of US 
population was effected by obesity of which 5% are considered as morbidly 
obese.  During obesity, fat accumulation in liver (steatosis) was observed 
which represents non-alcoholic fatty liver (Wanless and Lentz, 1990). It is well 
established that during obesity and other metabolic disorders several genes 
expression changes take place particularly in liver.  Few studies documented 
the coordinate regulation of drug transporter and nuclear receptor expression 
in steatosis.  Altered nuclear hormone expression in fatty liver, was taught to 
be one of the factors responsible for change in metabolic genes (Cheng et al., 
2008; More and Slitt, 2011).  Obesity and other metabolic syndrome 
components are also characterized with altered levels of metabolism-related 
hormones such as insulin, resistin, glucagon and amylin levels (Azuma et al., 
2003; Reinehr et al., 2007).  Hyperinsulinemia was observed during obese 
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and diabetic conditions.  No studies have shown relation between metabolism-
related hormones role in regulating drug transporters.  Recently, drugs that 
target these metabolism-related hormones are developed for treating obesity 
and diabetes (Schmitz et al., 2004).  There is a need to identify whether these 
metabolism-related hormones have role in regulating gene expression 
changes particularly drug transporter expression during development of 
obesity. 
3. Leptin and rodent models of obesity: 
There are of several models of obesity in rodents such as diet induced obesity 
or genetically modified obseity. Ob/ob mice are genetically modified obese 
model, these mice have a spontaneous mutation in Ob gene (leptin).  Leptin a 
hormone produced by adipose tissue both in human and rodent plays crucial 
role in food consumption (Frederich et al., 1995; Kennedy et al., 1997).  Leptin 
regulates food consumption by acting on the central nervous system as a 
negative feedback system for body fat accumulation (Elmquist et al., 1998; 
Schwartz et al., 2000).  Decreases in fat and body weight were observed with 
leptin supplements in normal and mice lacking Ob gene (Muzzin et al., 1996; 
Elmquist et al., 1998; Friedman and Halaas, 1998; Ahima and Flier, 2000; 
Schwartz et al., 2000).  Leptin levels in body correspond to amounts of fat 
tissue.  Leptin acts through membrane receptors (Ob-R), there are several sub 
types of OB-R receptors they differs by length, location and functionality 
(Kastin et al., 1999; Hileman et al., 2000; Martin et al., 2008).  Obese Zucker 
rat have mutated leptin receptor (fa, Ob-R gene), these rats display similar 
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conditions as ob/ob mice.  Both in rodent and humans, there is an increase in 
circulating leptin levels proportional to increase in adiposity in diet induced 
obesity (Li et al., 1997) .  Ob-Re is a soluble leptin receptor isoform and 
several other Serum Leptin Interacting Proteins (SLIPs) play crucial roles in 
regulating leptin activity both centrally and peripherally (Lammert et al., 2001; 
Zastrow et al., 2003; Chen et al., 2006). Leptin has no central action in 
neonatal mice despite fact that there are high levels of circulating levels of 
leptin.  In neonates, high expression of OB-Re leptin receptor, which act as 
leptin inhibitory protein was thought to be responsible for lack of leptin action 
over CNS during that age (Ahima et al., 1998; Pan et al., 2008).  These 
studies suggest that leptin has no or minimal regulation on food consumption 
in neonates, which is contrary to leptin action in adults. 
Adult ob/ob mice have well characterized models for obesity diabetes and 
steatosis that is part of non-alcoholic fatty liver disease.  Ob/ob mice have 
characteristic features such as hyperphagia, hyperglycemia, glucose 
intolerance, elevated plasma insulin, subfertility, hypometabolism and 
hypothermia (Lindstrom, 2007).  All these physiological changes were 
predominantly observed in ob/ob mice from four weeks of age (Dubuc, 1976).  
Previous studies show that leptin has minimal or no central action until mice 
are two weeks old; moreover ob/ob mice did not show any significant 
physiological changes until they reach adolescence. This suggests neonatal 
Ob mice should have normal physiological and gene expression changes as 
normal mice. Drug transporter expression is known to alter during several 
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metabolic conditions.  Both genetically modified and diet-induced obesity 
alters drug transporter expression.  Analyzing ontogeny of Ob mice hepatic 
drug transporter expression will provide an insight how lack of leptin action 
and increased levels of serum hormone levels can affect drug transporters 
expression. 
4. Bispheonl A: 
Bisphenol A (BPA) is a monomer used in plastic manufacturing. According to 
National Health and Nutrition Examination Survey, 92.6% of 2500 participants 
have BPA in urine samples (Calafat et al., 2008).  BPA exposure during 
gestation and lactation periods resulted in dysregulation of several aspects in 
pups.  The negative effects of BPA exposure are considered to be higher in 
children compared to adults may be due to low expression of elimination 
pathway.  Adverse effects of BPA exposure includes increased body weights 
in females, early onset of puberty, alterations in mammary glands and 
reproductive glands, changes metabolic features, causes insulin resistance, 
increases adipogenesis and predisposes to metabolic syndrome in pups 
(Alonso-Magdalena et al., 2006; Somm et al., 2009; Wei et al., 2011).  All 
these adverse effects shown by BPA exposure involve multiple mechanisms, 
such as epigenetic modulation and endocrine disruption.  In mice, methyl 
donor supplementation along with BPA treatment has muted epigenetic 
modulation shown by BPA (Dolinoy et al., 2007).  BPA acts as an endocrine 
disruptor by mimicking estrogen and binds to estrogen receptors (ER) such as 
ER-alpha and beta.  BPA is also known to act as an antagonist for thyroid 
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hormone receptors.  BPA developmental exposure in Avy mice has resulted in 
change in coat color of pups through epigenetic modulation which was muted 
by methyl donor supplementation along with BPA exposure (Dolinoy et al., 
2007).  BPA developmental exposure in these Avy mice altered sexual 
dimorphic gene expression and sexual traits expressed in adult mice 
(Jasarevic et al.; Mao et al.). 
BPA is highly metabolized in gut and liver, and eliminated by urinary and fecal 
excretion (Vandenberg et al., 2009).  Drug transporters play key role in 
elimination of BPA from body, as they are involved in elimination of BPA 
metabolites.  BPA-glucuronide and BPA-sulfate are the major metabolites 
formed in humans and mice (Vandenberg et al., 2009).  The Ugt2b family and 
Sult1a1 enzymes are major biotransformation enzymes involved in BPA 
conjugation (Nishiyama et al., 2002; Vandenberg et al., 2009).  Early 
developmental toxicity caused by BPA in neonates may be due to low 
expression of several Phase II enzymes compared to adults (Hines, 2008).  
Decrease in these Phase-II and drug transporter expression in liver may cause 
accumulation of BPA in body.  BPA metabolite elimination differs from rodent 
to human and non-human primates.  In rodents, BPA primarily is excreted by 
the biliary route whereas in human BPA undergoes urinary excretion 
(Vandenberg et al., 2009).  Some in vitro studies performed in hepatic 
carcinoma cells such as HepG2 cells showed BPA exposure has altered ABC 
drug transporter expression (Hanet et al., 2008).  To date, there are no studies 
reported or performed showing effects of BPA exposure on hepatic drug 
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transporters, yet transporters are vital to maintaining systemic levels of 
circulating hormones. Disruption of hepatic transporter expression may be one 
of the mechanisms by which endocrine disrupting compounds, such as BPA, 
elicit hormone-disrupting effects.  Evaluating whether BPA developmental 
exposure modulates hepatic drug transporter expression or not will provide 
valuable information about how environmental toxicant exposure through 
maternal diet affects pups xenobiotic and hormone metabolism. 
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ABSTRACT 
Purpose: Obesity is a predominant risk factor for metabolic syndrome, which is 
defined as a cluster of risk factors that occur simultaneously and increase the 
likelihood of coronary artery disease, stroke, and type-2 diabetes. One 
manifestation of metabolic syndrome is the development of hepatic steatosis 
in conjunction with insulin resistance. In recent years, the occurrence of 
obesity in the adult population has significantly increased, which warrants the 
need  for better  drug efficacy and toxicity prediction.  The purpose of this 
study was to determine whether clinical biomarkers and hormones could 
correlate with nuclear receptor and transporter-related pathways at different 
ages, in order to better predict altered drug metabolism or disposition. 
Methods: Livers from male and female C57BL/6 and ob/ob mice littermates at 
1, 3, 4 and 8 weeks of age were collected.  Serum hormone and mRNA levels 
were analyzed using a Luminex platform.  Correlation between physiological 
changes and gene expression was performed using canonical correlations. 
Results: Significant ontogenic changes in both C57BL/6 and ob/ob mice were 
observed during and post-weaning.  In males and females, the ontogenic 
pattern started to differ from week 3, but significant changes were observed at 
week 4 and 8 in ob/ob mice compared C57BL/6 mice.  Significant correlations 
were observed between physiological changes, hormones, and gene 
expression changes during development of obesity. 
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Conclusion: The correlation between physiological changes and gene 
expression indicate metabolism-related hormones can regulate or be co-
regulated with genes involved in drug metabolism and transport.  Specifically, 
in males correlations indicate serum resistin and glucagon can regulate 
hepatic Abc transporter expression. 
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INTRODUCTION 
Obesity is a metabolic disease characterized by an increased body mass 
index (BMI≥30).  Obesity is a predominant risk factor for metabolic syndrome 
(MetS), which encompasses increase in body weight, adipose tissue mass, 
insulin resistance, and serum hormone levels (Grundy, 2004).  One of the 
manifestations of metabolic syndrome is the development of hepatic lipid 
accumulation (e.g. steatosis), which represents non-alcoholic fatty liver 
disease (NAFLD) in conjunction with insulin resistance (Wanless and Lentz, 
1990).  There is a growing concern about absorption, distribution, metabolism, 
and excretion (ADME) in the obese population, as studies reveal an altered 
ADME in people affected with obesity and metabolic diseases (Brill et al., 
2012).  Ob/ob mice have a mutation in the Ob gene that encodes for the 
leptin, resulting in a phenotype that has many characteristics common to Mets.  
Due to lack of leptin, ob/ob mice exhibit hyperphagia, profound weight gain, 
hyperglycemia, glucose intolerance, elevated plasma insulin and severe 
hepatic steatosis (Lindstrom, 2007).  Most of these changes are observed 
predominantly in ob/ob mice from four weeks of age (Dubuc, 1976).  
Drug transporters are membrane bound proteins that facilitate both uptake and 
efflux of xenobiotics, endogenous compounds and their metabolites in various 
tissues including liver.  Hepatic transporter expression is an important 
determinant in maintaining systemic balance of endogenous compounds such 
as bile acids, hormones, and bilirubin (Lecureux et al., 2009).  ATP-binding 
cassette (Abc) transporters are kind of drug transporters, which are ATP-
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dependent membrane proteins that transport a wide variety of compounds.  
Multiple hepatic conditions can alter drug transporter expression, such as 
obesity, oxidative stress, inflammation, drug-induced liver injury, and 
environmental toxicants (Geier et al., 2003; Aleksunes et al., 2008; Cheng et 
al., 2008).  Previous studies document alterations in drug transporter and drug 
metabolizing enzyme expression (DME’s) in obese and diabetic conditions 
(Cheng et al., 2008; More and Slitt, 2011). 
In liver, transcription factors, such as pregnane X receptor (Pxr, Nr1i2), 
constitutive androstane receptor (Car, Nr	   1i3), farnesoid X receptor (Fxr, 
Nr1h4) and nuclear factor E2-related factor 2 (Nrf2, Nfe2l2) regulate the basal 
and inducible expression of biotransformation enzymes and Abc transporters 
(Klaassen and Slitt, 2005).  For example, Pxr and Car upregulate Cyp3a11 
and Cyp2b10 expression, whereas Nrf2 upregulates Nqo1 gene transcription 
and expression (Aleksunes et al., 2006).  With regard to transporters, hepatic 
Abcc2-4 induction by microsomal enzyme inducers is observed to be Nrf2-
dependent (Maher et al., 2005a).  Prototypical Pxr activators upregulate 
hepatic Abcc2, 3, Slc10a1 and Slco1a4 expression (Cheng et al., 2005b; 
Maher et al., 2005a; Cheng et al., 2007), whereas Car activators upregulate 
Abcc2-6 in liver (Cheng et al., 2005b; Maher et al., 2005a).  However, the 
mechanisms by which transcription factors regulate transporter expression 
during development of fatty liver disease are largely not well described.  An 
increase in Pxr, Car and Nrf2 mRNA expression with no changes in binding to 
consensus sequences was observed in livers of 9 week old ob/ob mice 
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compared to C57BL/6 mice (Xu et al., 2012), suggesting other mechanisms 
may be involved in the coordinate regulation of drug transporter and 
transcription factor expression in steatosis. 
Obesity alters levels of metabolic hormones, such as resistin, glucagon, insulin 
and incretins (Starke et al., 1984; Azuma et al., 2003; Reinehr et al., 2007), 
which could help explain the observed changes in gene expression.  Known 
consequence of obesity is insulin resistance accompanied by hyperglycemia 
(Kahn et al., 2006).  Although increased incretin such as glucagon like 
peptide-1 (GLP-1) levels are observed in obese people, GLP-1 activity 
associated with insulin secretion is decreased compared to lean individuals 
(Laferrere et al., 2007).  Several therapies that target these hormones have 
been identified for treatment of obesity and other metabolic diseases (Schmitz 
et al., 2004).  During obesity correlations have been identified between 
changes in serum resistin, leptin and insulin levels (Pantsulaia et al., 2007).  
As more incretins based therapies are being utilized to manage diabetes a 
component of Mets, it is critical to understand whether incretin hormones could 
modulate drug disposition. 
Ob/ob mice are commonly used to model MetS and fatty liver disease 
(Lindstrom, 2007).  This study aims to correlate typical clinical endpoints and 
metabolic hormones with hepatic transcription factoes, prototypical drug 
metabolizing enzyme (DME), and transporter mRNA expression. The findings 
of this study provide potential insight into possible measures and serum 
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biomarkers that can be used to predict potential ADME changes in obese 
patients. 
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MATERIALS AND METHODS 
Animals and husbandry. Heterozygous mice were mated and offspring were 
genotyped for sex and mutation of the leptin gene.  Tissues from male and 
female wild type (C57BL/6J) and homozygous (ob/ob) were collected at age of 
week 1, 3, 4, and 8 (n=4-5 per group).  Blood was collected and serum was 
obtained after centrifugation at 5,000 rpm for 5 minutes at 4°C.  Livers were 
collected, snap frozen in liquid nitrogen, and stored at -80°C for future 
analysis.  All animal experiments were approved by University of Rhode Island 
Institutional Animal Care and Use Committee (IACUC).   
Hematoxylin and eosin staining.  After collection, a small section of liver 
from the central lobe was fixed in formaldehyde for 24 h and then transferred 
to 75% ethanol prior to paraffin embedding.  Paraffin-embedded tissues were 
cut to approximately 5 micron sections, and stained with hematoxylin and 
eosin by standard histology protocols (AML Laboratories, Rockland, MD).   
RNA extraction.  Total RNA from livers was isolated by phenol-chloroform 
extraction method using RNA-Bee reagent (Tel-Test Inc., Friendswood, TX), 
according to the manufacturer’s protocol.  RNA concentration was quantified 
by absorbance at 260 nm using a Nanodrop ND1000 (Thermo Fisher 
Scientific, Waltham, MA) and the samples were diluted to 1 µg/µL.  
Formaldehyde–agarose gel electrophoresis followed by UV illumination was 
used to visualize RNA and confirm integrity. 
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QuantiGene® multiplex suspension array.  Mouse liver mRNA expression 
was determined using a Quantigene® Plex 2.0 assay (Panomics Inc., 
Fremont, CA) with a Bio-Plex System Array reader with Luminex 100 xMAP 
technology, and data was acquired using Bio-Plex Data Manager Software 
(Bio-Rad, Hercules, CA).  Assays were performed according to the 
manufacturer's protocol (Panomics, Inc.).  The optimal RNA input was 
determined prior to running the assay.  Briefly, 500 ng of total RNA was 
incubated overnight at 53°C with X-MAP beads containing oligonucleotide 
capture-probes, label extenders, and blockers.  On the next day, beads and 
bound target RNA were washed and subsequently incubated with amplifier at 
46°C for 1 hr.  Next, samples were washed and incubated with the label 
(biotin) at 46°C for 1 hr.  Samples were washed and incubated with 
streptavidin-conjugated R-phycoerythrin, which binds biotinylated probes, and 
incubated at room temperature for 30 min.  Streptavidin-conjugated R-
phycoerythrin fluorescence was then detected for each analyte within each 
sample.  Data was normalized with the average week 1 expression in C57BL/6 
mice and expressed as arbitrary units (AU). 
Branched DNA amplification (bDNA) assay.  Relative bile salt-export pump 
(Abcb11, Bsep) and Na+-taurocholate cotransporting polypeptide (Slc10a1, 
Ntcp)	   mRNA levels were quantified using bDNA assay using previously 
described probesets (Cheng et al., 2007).  All reagents for analysis including 
lysis buffer, amplifier/label probe diluent and substrate solution were supplied 
in the QuantiGene 1.0 assay kit (Panomics, Fremont, CA).  Briefly, the probe 
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set stocks containing capture extenders, label extenders, and blockers were 
diluted 1:100 in lysis buffer before use.  On day one, total RNA samples (10 
µg) were added to wells containing 50 µL of capture hybridization buffer and 
50 µL of diluted probe set.  The RNA was allowed to hybridize overnight with 
the probe set at 53°C.  On day two, subsequent hybridization steps were 
followed as detailed in the manufacturer’s protocol, and fluorescence was 
measured with a GloRunnerTM microplate luminometer interfaced with 
GloRunner DXL Software (Turner Biosystems, Sunnywale, CA).  The 
fluorescence for each well was reported as relative light units (RLU) per 10 µg 
of total RNA (Donepudi et al., 2012).  Data was normalized with the average of 
week 1 expression in C57BL/6 mice and expressed as arbitrary units (AU).  
Serum metabolism-related hormone levels.  Serum metabolism-related 
hormones were quantified using a Millipore 10-plex kit (MMHMAG-44K) on a 
Bioplex® multiple array system.  A custom Millipore-plex kit containing 
different targets such as insulin, glucagon, resistin, glucagon like peptide-1 
(GLP-1), amylin and leptin was used and   analyzed according to 
manufacturers protocol.  Fluorescence was detected on a Bioplex® multiple 
array reader system (BioRad, Hercules, CA). Data was collected by Bioplex® 
manager 5.0 software and plotted as average concentration (µg/mL).  
Correlation analysis. Correlations between the mRNA levels of genes related 
to drug metabolism and transcription factors were performed using either 
Statistica 9.1 software (Stat Soft, Inc., Tulsa, OK) or canonical correlation 
analysis (CCA).   Briefly, the  canonical correlation analysis data generated 
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was log transformed and distributed in 3 blocks such that block 1 contained 
gene expression of drug transporters and phase I enzymes, block 2 contained 
transcription factor expression, and block3 contained physiological data- 
serum hormone and, glucose levels, body and, liver weights. Cross block 
pairwise bivariate correlations were performed between each block and heat 
maps were generated.  Hierarchical clustering was performed using the same 
data with pearson correlation.  Data presented as heat maps or with r value, 
p≤0.05 is considered as a statistically significant correlation. 
Statistical analysis.  The statistical significance between groups was 
determined by factorial ANOVA followed by a Duncan’s Multiple-range post 
hoc test, using Statistica 9.1 software (Stat Soft, Inc., Tulsa, OK).  Data are 
presented as mean ± SE, with p ≤0.05 considered statistically significant.   
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RESULTS 
Tissue and body weights, blood glucose levels:  Figure 1A illustrates the 
body weights of male and female C57BL/6 and ob/ob mice.  At week 1 of age, 
body weight was similar between all groups. At weeks 4 and 8, ob/ob mice 
had significantly higher body weight compared to C57BL/6 mice, as 
anticipated.  Figure 1B illustrates serum glucose levels each group of mice. A 
2.3-fold age-dependent increase in serum glucose levels was observed  at 8 
weeks  compared to week1 C57BL/6 mice.  In male ob/ob mice, serum 
glucose levels increased with age at week 4 and 8 by 2.1 and 4.5-fold 
respectively, compared to week 1 ob/ob male mice.  In female ob/ob mice, 
serum glucose levels increased with age at week-3, 4 and 8 by 1.7, 1.9 and 
3.8-fold respectively compared to week 1 female ob/ob mice.  Serum glucose 
levels in both male and female ob/ob mice were significantly increased at 
week 8 compared to C57Bl/6 counterparts by 1.3-fold, these changes in serum 
glucose levels between ob/ob mice and C57BL/6 mice were not observed at 
early ages. 
Ontogeny of serum hormones in C57BL/6 and ob/ob mice.  Figure 1C 
illustrates serum hormone changes observed in both male and female 
C57BL/6 and ob/ob mice from weeks 1, 3, 4 and 8.  Serum hormone levels 
were similar between C57BL/6 and ob/ob mice at one week of age.  In male 
C57BL/6 mice, glucagon, resistin and GLP-1 decreased with age, but insulin 
and amylin did not.  In male C57BL/6 mice, serum glucagon, resistin, and 
GLP-1 levels were decreased by ~78% from week 3 compared to week 1.  
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However, in male ob/ob mice, serum insulin and amylin increased with age 
after week 4 by 4-fold.  Also, serum insulin, glucagon, resistin, GLP-1 and 
amylin levels were significantly elevated in male ob/ob mice compared to male 
C57BL/6 mice from 4 weeks of age. 
In female C57BL/6 mice serum glucagon, resistin and GLP-1 levels decreased 
with age. However, serum insulin and amylin levels were similar at all weeks 
assessed.  In female ob/ob mice, insulin and amylin increased after four 
weeks of age while glucagon, resistin, and GLP-1 levels decreased by 57%, 
31% and 40% respectively, compared to 1 week old female ob/ob mice.  
Similar to observations in males, all serum hormone levels were increased at 8 
week time point in females ob/ob mice compared to corresponding C57BL/6 
females. 
Transporter and prototypical metabolizing enzyme expression livers of 
C57BL/6 and ob/ob mice. Figure 2 illustrates hepatic efflux drug transporter 
expression observed in both male and female C57BL/6 and ob/ob mice.  In 
C57BL/6 and ob/ob mice ontogenic changes were observed in Abc transporter 
expression for Abcc1, 3, 4, 5 and Abcb11 in both males and females.  Similar 
to physiological changes, no significant changes were observed in Abc 
transporters expression between one-week old male and female C57BL/6 and 
ob/ob mice.  In male ob/ob mice, Abcc3, 4 and Abcg2 mRNA expression was 
increased significantly compared to C57BL/6 mice by 1.8, 7 and 2.3-fold 
respectively.  A similar increase was observed in female ob/ob mice, with 
Abcc3, 4 and Abcg2 mRNA expression compared to female C57BL/6 mice.  In 
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contrast to males, female ob/ob mice have significant decrease in Abcb11 
mRNA expression by 49% compared to female C57BL/6 mice.  Most of these 
significant changes in both male and female ob/ob mice were observed from 4 
weeks of age. 
Figure 3 illustrates hepatic uptake drug transporter expression in both male 
and female C57BL/6 and ob/ob mice. In both male and female C57BL/6 mice, 
Slco1a1 expression increased significantly at week 8 compared to week 1 by 
219 and 95-fold respectively. However these changes in Slco1a1 mRNA levels 
were not observed in both male and female ob/ob mice.  Interestingly, in 8-
week old male and female ob/ob mice, Slco1a1 expression was significantly 
decreased by 97 and 98% respectively, compared to their C57BL/6 
counterparts. In male and female, C57Bl/6 and ob/ob mice, ontogenic 
changes in Slco1a4 were observed only at 3 and 4 weeks of their age but not 
in week 8 old mice compared to week 1.   
Figure 4 illustrates hepatic DME expression observed in both male and female 
C57BL/6 and ob/ob mice.  In male and female ob/ob mice Cyp2b20 and 4a14 
mRNA expression significantly increased with age compared to week 1 
whereas no ontogenic changes were observed in C57BL/6 mice.  Changes in 
mRNA expression with age in Cyp3a11 were observed from 3 weeks of age 
whereas changes in Cyp2b20 and 4a14 mRNA expression were observed 
from 4 weeks of age.   Male ob/ob mice also showed a significant increase in 
cyp2b20 and 4a14 expression from 4 weeks of age compared to their 
C57BL/6 counterparts by 4.3 and 2.2-fold respectively.  Female ob/ob mice 
	   31 
had significant increase in expression of Cyp3a11 (1.3 fold) and Cyp2b20 (1.8 
fold) expression compared to C57BL/6 mice at only week-4.  Cyp4a14 mRNA 
expression in female ob/ob mice significantly greater at both 4 and 8 weeks by 
2.5 and 3.1-fold respectively compared to female C57BL/6 mice. 
Hepatic transcription factor expression of C57BL/6 and ob/ob mice.  
Figure 5 illustrates the hepatic transcription factor mRNA expression levels in 
livers of male and female C57BL/6 and ob/ob mice.  In male C57BL/6 and 
ob/ob mice, there were no significant ontogenic changes in transcription factor 
mRNA expression, except Nrf2 and Ppar-α.  In male ob/ob mice, Nrf2 mRNA 
expression increased at week-8 by 2 fold compared to week-1.  At week-8, 
Car, Fxr and Nrf2 mRNA expression significantly increased by 2-3 fold, in 
male ob/ob compare to male C57BL/6 mice.  In female C57BL/6 mice, Pxr 
mRNA expression decreased with age by 51% compared to week-1, however 
this is not observed in female ob/ob mice.  In female ob/ob mice, only Fxr 
mRNA levels significantly increased by 2.5 fold at 3 and 4 weeks of their age 
compared to week-1.  In females no significant changes were observed in 
transcription factors expression between ob/ob and C57BL/6 mice. 
Correlation analysis between gene expression changes and 
phenotypical changes.  Role of gender and leptin in ontogenic changes in 
hepatic gene expression pattern is depicted pictorially using heat maps (Figure 
6 & 7).  Gene expression values were log transformed to generate heat maps 
using R-language.  These heat maps strongly indicate leptin and gender plays 
a huge role in the regulation of hepatic genes involved in metabolism and 
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disposition. Difference in ontogenic changes in ob/ob mice and C57BL/6 mice 
in both male and female illustrates influence of leptin over peripheral tissues 
apart its regulation of satiety at central nervous system.  Table 1 & 2 illustrates 
correlations between physiological factors, such as metabolic hormone levels, 
serum glucose, and body and liver weights were performed using canonical 
correlations.  Canonical correlations were performed to identify physiological 
factors, which may have a potential role as a biomarker during development of 
obesity (Table 1 & 2).  In males, serum resistin and insulin levels correlate with 
all physiological factors, whereas in female mice, serum resistin, insulin and 
amylin correlate with other physiological factors during development of 
obesity.  In both males and females, these correlations between physiological 
factors suggest that changes in serum resistin levels may be associated with 
development of obesity irrespective of gender.  
Furthermore, canonical correlations were performed between physiological 
factors and gene expression to identify relationships between changes in gene 
expression during development of obesity and common parameters used to 
assess MetS.  Figure 8 illustrates correlations for physiological factors such as 
hormone level, body, and liver weights with drug transporter and DME 
expression in male and female mice presented as heat maps.  In males and 
females, serum amylin levels correlated with Abcc4, Abcg2, Cyp2b20 and 
4a14 expression.  Correlation between other physiological factors and drug 
transporters expression differ between males and females.  For example, 
serum resistin levels correlated with Abcc1, 4, 5, Abcb1a, Abcb11, Slco1a1, 
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Cyp3a11 and 4a14 expression in male mice, whereas resistin levels correlated 
to Abcc1, Abcb11, Slco1a1, 1a4, Slc10a1, Cyp3a11, 2b20 and 2e1 in females.  
Furthermore, serum insulin concentrations correlated to Abcc4, Abcg2, 
Cyp2b20 and 4a14 expression in males whereas it is correlated to Abcc4, 
Abcg2 and Slco1a1 expression in females.  Serum glucagon concentrations 
correlated with Abcc1, 4, Abcg2, Abcb1a, Abcb11, Slco1a1, Cyp3a11 and 
Cyp4a14 expression in males, but correlated to Abcc6, Abcb11, Slco1a4, 1b2 
and Slc10a1 expression in females.  In males, serum GLP-1 concentrations 
were correlated with only Abcb11, Slco1a4, Cyp3a11 and 2e1 expression 
whereas in females it is correlated with Abcc2, 3, Abcb11, Slco1a1, 1a4, 1b2, 
Cyp3a11, 2b20 and 2e1 expression.  In males, serum glucose concentrations 
correlated to Abcc1, 3, 5, 6, Abcb1a, Abcb11, Cyp3a11 and 2b20 expression 
whereas it is correlated only to Abcc3-5, Cyp3a11 and 2b20 in females.  Both 
body and liver weights correlated to Abcc1, 3, 5, 6, Abcb1a, abcb11, Slco1a1, 
Cyp3a11 and 2b20 expression in male mice, whereas in females they 
correlated with Abcc1, 3- 6, Cyp3a11 and 2b20 expression. 
Figure 9 illustrates the correlation (heat maps) between transcription factors 
with drug transporters and phase I enzymes expression in male and female 
mice.  Correlation between transcription factors, drug transporters, and DME 
expression was performed using canonical correlations and the data 
generated is presented as a heat map.  In males, during development of 
obesity and MetS, expression patterns of all Abc transporters except Abcb11 
were correlated with all transcription factors analyzed with minor exceptions.  
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In male mice, Abcc3 expression did not correlate with Pxr, Car, Ppar-α, and 
Ppargc1α expression, whereas Abcc5 is not correlated with Fxr.  Correlation 
between Abc transporters and transcription factors showed gender dependent 
changes during development of obesity.  Interestingly, in female mice only 
Abcc2, 6 and Abcb1a expression was correlated with all transcription factors 
analyzed, whereas Abcg2 expression was correlated with all transcription 
factors except Car during development of obesity.  In female mice, Abcc3 
expression was correlated to Car, Lxr, Fxr and Nrf2 expression, whereas 
Abcc4 expression was correlated to Pxr, Lxr, Fxr and Nrf2 expression. In both 
male and female mice, uptake transporter Slco1b2 expression was correlated 
to all transcription factors expression whereas Slco1a4 expression was 
correlated with Car, Lxr, Fxr, Nrf2 and Ppargc1α expression.  Drug 
metabolizing enzymes such as Cyp2e1 and 4a14 expression was correlated 
with all transcription factors expression in both male and female mice.  In male 
mice, Cyp2b20 expression was correlated to Lxr, Fxr and Nrf2 expression 
whereas in females Cyp3a11 and 2b20 were correlated to Car, Lxr, Fxr and 
Nrf2 expression. 
DISCUSSION 
Obesity and the subsequent MetS are major concerns in the United States 
(Grundy, 2004).  Non-alcoholic fatty liver disease (NAFLD) is a manifestation 
of MetS.  About 15-39% of the US population is affected with NAFLD, and 
about 95% of the morbidly obese are diagnosed with NAFLD (Younossi et al., 
2002; Collantes et al., 2004).  Ob/ob mice are used to model MetS and 
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NAFLD because they have multiple markers that are elevated in a manner 
similar to humans with uncontrolled MetS – morbid obesity, markedly elevated 
glucose levels, insulin resistance and dysregulation of metabolic hormones, 
dyslipidemia, increased markers of inflammation, and hepatic steatosis 
(Lindstrom, 2007).  Studies have shown alteration in drug transporter and drug 
metabolizing enzyme expression during NAFLD, which resulted in altered drug 
elimination (Barshop et al.; Lickteig et al., 2007; Cheng et al., 2008; Hardwick 
et al., 2012).  Moreover, changes in hepatic uptake and efflux transporter 
expression in ob/ob mice is somewhat similar to changes observed in diet-
induced obese mice and human steatotic livers (Cheng et al., 2008; More and 
Slitt, 2011). 
Previous studies have shown that expression of several DMEs and drug 
transporters in C57BL/6 mice change with age (Cheng et al., 2005a; Maher et 
al., 2005b; Cui et al., 2010).  In this study we characterized ontogeny of 
transporters along with phase-I enzymes in coordination with transcription 
factors in both C57BL/6 and ob/ob mice.  We selected four different ages (e.g. 
week-1, 3, 4 and 8) to capture different times during the progression of MetS.  
Ontogeny of drug transporters in both male and female C57BL/6 mice we 
observed are similar to published studies (Cheng et al., 2005a; Maher et al., 
2005b).  Changes observed in transporters, phase-I enzymes, and 
transcription factors expression in ob/ob mice compared to C57BL/6 mice 
were similar to published studies (Cheng et al., 2008; Xu et al., 2012). 
As mentioned earlier ob/ob mice have characteristic physiological changes.  At 
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week-1 body and liver weights do not show any significant difference from 
their lean counterparts.  However, increased body and liver weight were 
observed with development of obesity in ob/ob mice irrespective of gender 
(Figure 1A and 11). These observations with body and liver weights are 
consistent with previously published studies (Dubuc, 1976). In ob/ob mice, 
similar to body and liver weight changes, hyperglycemia developed with 
development of obesity.  Liver histology was similar at week-1, steatosis was 
observed at week-3, but prominent changes in histology presented at week-4 
(Figure 12). Metabolic-related hormones concentrations altered with 
development of obesity although their concentrations are similar to lean 
littermates at early ages.  Interestingly, correlations between physiological 
changes showed serum resistin and insulin levels have significant correlations 
in both males and female mice during development of obesity.  Resistin is 
circulating protein secreted by adipose tissue, which plays an important role in 
causing insulin resistance (Steppan and Lazar, 2002).  In diet-induced obese 
mice, administration of anti-resistin antibody corrected hyperglycemia and 
insulin resistance, which are key factors for causing obesity (Steppan and 
Lazar, 2002).  Our results from correlation analysis also indicates changes in 
serum resistin levels can be a possible biomarker, which can predict changes 
liver gene expression associated with MetS.   
Incretins, like amylin and GLP-1, play a key role in insulin secretion and 
maintaining blood glucose levels.  In both male and female ob/ob mice, GLP-1 
levels were changed at week-8, whereas amylin levels increased from week-4.  
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Amylin is secreted along with insulin from pancreas and involved in 
maintaining serum glucose levels (Moreno et al., 2011). Changes in amylin 
and insulin levels in our study were observed at same time.  Moreover, 
changes in amylin and insulin levels along with resistin showed significant 
correlation with other physiological parameters analyzed in females during 
development of obesity.  As mentioned by Reinehr et al 2007, 
hyperamylinemia was thought to be one of the important factors in causing 
several metabolic abnormalities during obesity and MetS (Reinehr et al., 
2007).  Recently new incretin based drug therapies for MetS such as amylin 
and GLP-1 agonists are gaining importance (Schmitz et al., 2004).  Correlation 
observed in our study indicates alteration in incretin levels may alter several 
physiological factors and hepatic metabolism-related gene expressions 
eliciting need to consider possible changes in xenobiotic metabolism and 
disposition in people undergoing multiple medications along with incretin 
based therapies.  Post market studies Indicates, that patient under GLP-1 
agonist therapies has 1.93 fold increase in occurrence of biliary infections 
such as    cholelithiasis, which can be caused due to altered hepatic Abc 
transporter expression. Correlation observed in our study and post market 
analysis of incretin based therapies support that possibility of hepatic drug 
transporter regulation by metabolic hormones. 
 
Abc transporters comprise the majority of hepatic efflux pumps, which efflux 
compounds from hepatocytes into bile or blood (Faber et al., 2003).  In adult 
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mice livers, relative Abcc1 and 4 are low, whereas Abcc3 expression is 
moderate, and Abcc6 is high (Maher et al., 2005b).  In both C57BL/6 and 
ob/ob mice, Abcc1 and 5 are expressed highly at week1 and decreased with 
age.  This pattern of high expression at initial stages and decrease at later age 
period in expression of Abcc1 is also observed in liver regeneration after 
undergoing 90% hepatectomy, indicating Abcc1 to have a lesser role in adult 
liver (Kimura et al., 2012).  Abcc3 is highly inducible basolateral efflux 
transporter that can cause altered vectorial disposition of xenobiotics (Slitt et 
al., 2003).  Abcc3 and 4 play key role in efflux of several xenobiotics and 
endogenous compounds such as estrogen and bile acid conjugates. Abcc 4 
protects hepatocyte from bile acid toxicity during cholestatic conditions 
(Mennone et al., 2006).  In both male and female C57BL/6 mice there is a 
slight increase although not statistical difference was observed in Abcc3 and 4 
expressions with age.  In both males and females obesity increased Abcc3 
and 4 mRNA levels with age as well as compared to their lean littermates.  
Apical efflux transporters such as Abcc2, Abcg2, Abcb1a and Abcb11 plays 
major role in excretion of xenobiotics and endogenous substances from liver to 
bile.  In both male and female mice, Abcc2 and Abcb1a mRNA levels are 
unaltered with age and obesity.   Previous studies indicated no change in 
mRNA levels and increase in protein levels of Abcc2 in ob/ob mice, which is 
consistent with our results (Cheng et al., 2008).  Abcc2 expression during 
obesity is species specific; in obese zucker rats Abcc2 expression decreases 
whereas it increases in ob/ob mice, but in humans there is no change with 
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obesity (Pizarro et al., 2004; Cheng et al., 2008; More and Slitt, 2011).  In 
male ob/ob mice Abcb11 expression did not alter compared to their lean 
littermates whereas in females Abcb11 expression decreased with progression 
of obesity.  Gender specific difference in Abcb11 expression pattern may be 
due to gender specific difference in growth hormone responsiveness in obesity 
(Cocchi et al., 1993) which is known to regulate Abcb11 expression (Cheng et 
al., 2007).  Previous studies showed that Abc transporter expression is 
regulated by several transcription factors (Maher et al., 2005a).  Interestingly, 
significant correlations were observed between hepatic Abc transporters and 
transcription factors expression during development of obesity.  These 
correlations during development of obesity between transcription factors and 
hepatic efflux transporters showed gender dependent changes.  Gender 
dependent changes in correlation between Abc transporters and transcription 
factors are much more pronounced in week-8 mice (Table 3 and 4). 
Hepatic uptake transporter Slco1a1 mRNA levels increased with age in 
C57BL/6 mice whereas in ob/ob mice it remained unchanged. In both male 
and female ob/ob mice Slco1a1 mRNA levels decreased significantly at week-
8.  Previous studies shown Slco1a1 mRNA expression is androgen dependent 
and negatively regulated by microsomal enzyme inducers that activate 
transcription factors Pxr, Car, Ppar-α and Nrf2 (Lu et al., 1996; Cheng et al., 
2005b).  Ob/ob mice have decreased  androgen levels (Swerdloff et al., 1976) 
and increase in transcription factors  expression (Xu et al., 2012), which 
explain decrease in Slco1a1 expression compared to C57BL/6 counterparts as 
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they become old.  Moreover in males, at week-8 age Slco1a1 expression was 
negatively correlated with all transcription factors that are analyazed, although 
these correlations are not significant (Table 3).  Obesity did not affect the 
ontogeny of Slco1a4, 1b2 and Slc10a1, which is contrary to previously 
published studies.  Differences in our results are may be due to age, 
previously published studies showed altered hepatic Slco1a4, 1b2 and 
Slc10a1 expression in week-11 old mice (Cheng et al., 2008), moreover 
hepatic uptake transporters are shown to change their expression pattern with 
age (Fu et al., 2012).  
Several studies have shown correlations and alteration in serum hormone 
levels during metabolic disorders.  Studies also showed hormones such as 
estrogen, progesterone and androgens could alter hepatic uptake and efflux 
transporter expression (Geier et al., 2003; Kalabis et al., 2007).  No studies 
have documented correlation with change in drug transporter expression with 
metabolism-related hormones, which are known to change in obesity.  Acute 
or chronic administration of metabolism-related hormones such as glucagon 
and GLP-2 altered transporter expression and function.  GLP-2 an incretin 
secreted along with GLP-1, which acts majorly on intestines was shown to 
regulate Abcc2 expression in intestine (Villanueva et al., 2010).  In human and 
rat hepatocytes, short-term glucagon treatment altered Abcc3 function 
(Chandra et al., 2005).  Not only transporters but also phase-II enzymes such 
as glutathione transferases expression were altered with glucagon and insulin 
treatment (Kim et al., 2003), indicating metabolism related hormones have a 
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potential to alter drug metabolism and related gene expression.  In males, 
serum resistin, glucagon and glucose levels are correlated with most of 
hepatic Abc transporter expression compared to serum amylin, insulin and 
GLP-1 levels.  In females, serum glucose showed more correlations with 
hepatic Abc transporter expression than serum metabolism-related hormones. 
Apart from serum metabolism related hormones and glucose levels, body and 
liver weights have shown high correlation with all hepatic Abc transporters 
analyzed (Figure 8).  Not only hepatic Abc transporters but overall, serum 
glucose, and body and liver weight stood as a markers for change in gene 
expression and physiological factors during development of obesity (Figure 
10).  In females, during development of obesity hepatic uptake transporter 
mRNA expressions were correlated with serum levels of resistin, glucagon and 
GLP-1 (Figure 8B).  These correlations indicate that not only sex related 
hormones such as estrogen and testosterone (Lu et al., 1996; Geier et al., 
2003) but also hormone involved in energy metabolism such as resistin, 
glucagon and GLP-1 have a role in regulation hepatic uptake transporters.  
Phase-I DMEs such as Cyp3a11 and 2e1 were not altered with obesity.  
Cyp2e1 expression during obesity and diabetes is species-specific.  In 
humans, Cyp2e1 is increased during obesity and diabetes whereas in mice it 
either remained unchanged or decreased (Enriquez et al., 1999; Wang et al., 
2003; Cheng et al., 2008).  In both male and female ob/ob mice Cyp4a14 
expression increased with development of obesity.  Cyp4a plays a key role in 
fatty acid metabolism and is shown to be upregulated in adult male ob/ob mice 
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(Cheng et al., 2008).  In males, Cyp2b20 mRNA levels increased with 
development of obesity compared to C57BL/6 mice whereas in female 
Cyp2b20 mRNA levels remained unchanged.  These gender specific changes 
in Cyp2b20 are observed in other model such as treatment with phenobarbital, 
which is an inducer of Cyp2b family (Larsen et al., 1994; Cheng et al., 2008).  
Insulin treatment altered Cyp3a, 2e1 and 4a expression in hepatocytes (Kim et 
al., 2003), indicating metabolism-related hormones can regulate phase-I 
enzyme expression.  Our results indicated that in female mice Cyp enzyme 
expression during development of obesity is mostly correlated to resistin and 
GLP-1, whereas in males these correlations are variable.  Sexually dimorphic 
regulation of Cyp enzymes might be responsible for gender specific 
differences in expression and correlations with metabolism related hormones 
(Hernandez et al., 2009).  
In summary, ob/ob mice are indistinguishable from their lean littermates at 
week-1.  Interestingly, during week1 in both male and females there are no 
significant changes in transporter, DME’s and transcription factors mRNA 
levels.  Not only mRNA levels, even physiological changes such as steatosis, 
metabolism-related hormone levels, body and liver weight are similar between 
ob/ob and C5BL/6 mice at week-1.  In both males and females, although 
ontogeny pattern started to differ from week-3 in ob/ob mice compared 
C57Bl/6 mice, significant changes were observed in week-4 and 8.  
IConsistent with previous studies, significant changes in physiological factors 
like hyperglycemia and insulin resistance were observed after weaning 
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(Dubuc, 1976; Lindstrom, 2007).  Correlation in drug transporters and DME’s 
expression with metabolism-related hormones in a model of obesity and MetS 
indicates changes in these hormones can alter ADME of xenobiotics and 
endogenous compounds.  Although physiological changes analyzed did not 
show up as a biomarker for prediction in gene expression changes, the 
correlation indicated that metabolism-related hormones analyzed were either 
co-regulated or involved in regulation of hepatic gene expression, which needs 
further investigation.  Finally, this study gives an idea about how changes in 
expression of drug metabolism related genes could occur at different stages of 
obesity and diabetes development.  
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Figure 1. Effect of age and leptin deficiency on phenotypical changes in 
C57BL/6 and ob/ob mice.  (A) Body weights of both male and female, 
C57BL/6 and ob/ob mice at week1, 3, 4 and 8.  (B) Serum glucose levels of 
both male and female, C57BL/6 and ob/ob mice at week1, 3, 4 and 8.  Serum 
glucose concentration was determined by glucose assay kit.  Data is 
presented as average concentration (mg/dl) ± S.E.M. (n=4-5 mice per group).  
(C) Metabolism-related hormone levels of both male and female, C57BL/6 and 
ob/ob mice at week1, 3, 4 and 8.  Metabolism-related hormone levels in 
C57BL/6 and ob/ob mice were quantified in serum collected from female and 
male C57BL/6 and ob/ob mice at 1, 3, 4, and 8 weeks of age (n= 4-5 for each 
group).  Hormones were quantified using a luminex-based assay.  Data is 
presented as average concentration (µg/ml)±S.E.M. (n=4-5 mice per group).  
Asterisks (*) represent a statistical difference between wild type and ob/ob of 
same age group and pound (#) represent a statistical difference with respect 
to week-1 mice (p≤0.05). 
Figure 2.  Effect of age and leptin deficiency on hepatic Abc drug 
transporters expression in both C57BL/6 and ob/ob mice.  Total RNA was 
isolated from livers of wild-type and ob/ob mice.  Hepatic ATP-binding cassette 
(Abc) transporter mRNA levels was quantified by the QGP 2.0 Plex assay.  
Data is presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per 
group).  Data presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per 
group).  Asterisks (*) represent a statistical difference between wild type and 
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ob/ob of same age group and pound (#) represent a statistical difference with 
respect to week-1 mice (p≤0.05). 
Figure 3.  Effect of age and leptin deficiency on hepatic uptake drug 
transporters expression in both C57BL/6 and ob/ob mice.  Total RNA was 
isolated from livers of wild-type and ob/ob mice.  Hepatic uptake transporter 
such as organic anion transport polypeptides (Oatps, Slco’s) and Na+-
taurocholate cotransporting polypeptide (Slc10a1, Ntcp) mRNA levels was 
quantified by the QGP 2.0 Plex assay.  Data is presented as mean arbitrary 
units (AU) ± S.E.M. (n=4-5 mice per group.  Asterisks (*) represent a statistical 
difference between wild type and ob/ob of same age group and pound (#) 
represent a statistical difference with respect to week-1 mice (p≤0.05). 
Figure 4.  Effect of age and leptin deficiency on hepatic drug 
metabolizing enzymes (DME) expression in both C57BL/6 and ob/ob 
mice.  Total RNA was isolated from livers of wild-type and ob/ob mice.  
Hepatic DME’s such as Cyp3a11, 2e1, 2b20 and 4a14 expression was 
quantified with QGP 2.0 plex assay.  Data presented as mean arbitrary units 
(AU) ± S.E.M. (n=4-5 mice per group).  Asterisks (*) represent a statistical 
difference between wild type and ob/ob of same age group and pound (#) 
represent a statistical difference with respect to week-1 mice (p≤0.05). 
Figure 5.  Effect of age and leptin deficiency on hepatic transcription 
factors expression in both C57BL/6 and ob/ob mice.  Total RNA was 
isolated from wild type and ob/ob mice livers, mRNA expression of Pxr, Car, 
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Lxr, Fxr, Nrf2, Ppar-α and Ppargc1α was analyzed with QGP 2.0 plex assay.  
Data presented as mean arbitrary units (AU) ± S.E.M. (n=4-5 mice per group).  
Asterisks (*) represent a statistical difference between wild type and ob/ob of 
same age group and pound (#) represent a statistical difference with respect 
to week-1 mice (p≤0.05).  
Figure 6.  Heat maps for gene expression analysis performed in both 
male C57BL/6 and ob/ob mice.  Hepatic gene expression values from week-
1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and heat maps 
were generated using g-plots in R language. 
Figure 7.  Heat maps for gene expression analysis performed in both 
female C57BL/6 and ob/ob mice.  Hepatic gene expression values from 
week-1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and heat 
maps were generated using g-plots in R language. 
 
Figure 8.  Correlation (heatmaps) between physiological factors with 
hepatic drug transporters and DME’s expression during development of 
obesity in male (A) and female (B) mice.  Hepatic gene expression from 
week-1, 3, 4, and 8, C57BL/6 and ob/ob mice are log transformed and data 
set was divided into two blocks. Block-1 contains hepatic drug transporters 
and DME’s expression and block-2 contains hepatic transcription factors 
expression.  Correlations between block-1 and 2 were performed using 
canonical correlations.  Data displayed as heat maps with highest positive 
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correlations considered as black and highest negative correlation are 
considered as red 
Figure 9.  Correlation (heatmaps) between transcription factors with drug 
transporters and DME’s expression during development of obesity in 
male (A) and female (B) mice.  Hepatic gene expression and physiological 
factors such as body, and liver weights, serum metabolism-related factors 
such as insulin, glucagon, resistin and amylin levels from week-1, 3, 4, and 8, 
C57BL/6 and ob/ob mice are log transformed.  Log transformed data set was 
divided into two block such that one of the block contains hepatic gene 
expression drug transporters and DME’s expression and other block contains 
physiological factors.  Correlations between both block were performed using 
canonical correlations.  Data displayed as heat maps with highest positive 
correlations considered as black and highest negative correlation are 
considered as red 
Figure 10. Hierarchical clustering of log transformed variables using 
Pearson correlation as a similarity measure.  Gene expression of drug 
transporters, DMEs and physiological factors was correlated with each other.  
Hierarchical clustering was performed using canonical correlations.	  
Figure 11. Effect of age and leptin deficiency on liver weights in C57Bl/6 
and ob/ob mice.  Liver weight of both male and female, C57Bl/6 and ob/ob 
mice at week1, 3, 4 and 8.   Asterisks (*) represent a statistical difference 
	   56 
between wild type and ob/ob of same age group and pound (#) represent a 
statistical difference with respect to week-1 mice.  
Figure 12. Effect of age and leptin deficiency on liver pathology.  A) 
Representative liver pathology in male C57Bl/6 and ob/ob mice at week 1, 3, 
4, and 8 (n=1 for each group).  B) Representative liver pathology in female 
C57Bl/6 and ob/ob mice at week 1, 3, 4, and 8 (n=1 for each group).  
Representative photomicrographs of Hematoxylin and Eosin stains of liver 
sections (200x).   
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Table 1. Correlation matrices for variables in phenotypical factors during 
development of obesity in male mice.  Data presented as r values, * value 
indicates significant correlation (p≤0.05). 
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Table 2. Correlation matrices for variables in phenotypical factors during 
development of obesity in female mice.  Data presented as r values, * value 
indicates significant correlation (p≤0.05). 
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Table 3. Correlation of hepatic transcription factors expression with 
hepatic drug transporters and DME’s expression in adult (week-8 old) 
male mice.  Data presented as r values, * value indicates significant 
correlation (p≤0.05).  
 
 Male Pxr Car Lxr Fxr Nrf2 Ppar-α Ppargc1a 
Abcc1 0.95* 0.97* 0.98* 0.98* 0.93* 0.99* 0.95* 
Abcc2 0.90* 0.98* 0.97* 0.92* 0.89* 0.97* 0.96* 
Abcc3 0.96* 0.91* 0.93* 0.97* 0.95* 0.94* 0.94* 
Abcc4 0.91* 0.83* 0.90* 0.93* 0.91* 0.87* 0.89* 
Abcc5 0.89* 0.96* 0.93* 0.91* 0.86* 0.95* 0.91* 
Abcc6 0.65* 0.73* 0.62  0.58  0.51  0.65* 0.68* 
Abcg2 0.97* 0.97* 0.97* 0.99* 0.93* 0.98* 0.96* 
Abcb1a 0.81* 0.71* 0.81* 0.80* 0.85* 0.76* 0.80* 
Bsep 0.01  0.11 -0.02 -0.02 0.08  0.03 -0.01 
Slco1a1 -0.35 -0.15 -0.33 -0.39 -0.49 -0.29 -0.27 
Slco1a4 0.91* 0.97* 0.99* 0.93* 0.93* 0.98* 0.96* 
Slco1b2 0.28  0.50 0.39  0.30  0.30 0.41  0.43 
Ntcp 0.47  0.30 0.26  0.42  0.44  0.28  0.28 
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Table 4. Correlation of hepatic transcription factors expression with 
hepatic drug transporters and DME’s expression in adult (week-8 old) 
female mice.  Data presented as r values, * value indicates significant 
correlation (p≤0.05). 
 
 Female Pxr Car Lxr Fxr Nrf2 Ppar-α Ppargc1a 
Abcc1 -0.60 -0.68* -0.05 -0.30 -0.05 -0.61 -0.62 
Abcc2 0.64  0.57  0.68* 0.48  0.60 0.79* 0.49 
Abcc3 0.25  -0.28 0.81* 0.49  0.89* 0.23 0.07 
Abcc4 -0.02 -0.54 0.67* 0.20  0.76* -0.08 -0.28 
Abcc5 0.17  0.35  0.24  0.42  0.20  0.42 0.67* 
Abcc6 0.66  0.94* 0.03  0.18  -0.09 0.76* 0.63  
Abcg2 0.21  -0.39 0.79* 0.41  0.81* 0.11  -0.19 
Abcb1a 0.82* 0.52  0.61 0.28 0.48  0.72* 0.48  
Bsep 0.09  0.35  -0.35 0.11  -0.38 0.15  0.41 
Slco1a1 0.48  0.86* -0.22 0.27  -0.43 0.59  0.39 
Slco1a4 0.18  0.38  -0.14 0.33 -0.20 0.29  0.55 
Slco1b2 0.65  0.63 0.51  0.72 0.46 0.82* 0.82* 
Ntcp 0.31  0.35 -0.22 -0.27 -0.17 0.15 0.30  
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ABSTRACT 
BPA is a synthetic xenostrogen used in plastic manufacturing.  Multiple studies 
in rodents demonstrate that developmental BPA exposure results in 
physiological, behavioral,and gene expression changes through multiple 
mechanisms – including epigenetic modifications. However, the impact of 
developmental BPA exposure on liver function was less known; as liver being 
a crucial determinant for systemic hormone concentrations and, chemical 
detoxification and clearance.  The purpose of this study was to investigate the 
effect of developmental BPA exposure on the expression of hepatic Phase-II 
and Abc transporter expression involved in liver clearance processes and BPA 
metabolism.  Female C57BL/6 (a/a) mice were fed either low or high dose of 
BPA (50 µg or 50mg/kg diet) or ethinyl estradiol (EE) (0.1ug/kg diet) or BPA 
(50mg/kg diet) with genistein (250 mg/kg diet) or AIN93 Control diet with 7% 
corn oil from 2 weeks pre-mating with male Avy/a mice.  BPA exposure was 
maintained through the breeding and lactation period.  Livers were collected 
from male offsprings after PND 135.  Developmental exposure to BPA and EE 
downregulated hepatic drug transporters and Phase II enzyme expression, 
involved in BPA metabolism and excretion whereas, genistein co-
administration reversed these changes.  Decrease in Nrf2 mRNA expression 
and binding activity could be partially responsible for downregulation of 
hepatic Phase II enzymes and drug transporter expression.  Further, increase 
in expression of Hdacs upon BPA exposure could be responsible for 
decreased transcription factor expression and activity.  Our data suggest that 
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developmental BPA and EE exposure may work via similar pathways, and 
greatly affect the expression of key hepatic genes involved in BPA and 
hormone metabolism and clearance.  
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INTRODUCTION 
The liver is the major organ for metabolism and clearance; with a significant 
role in determining circulating systemic endocrine hormone and bile acid 
concentrations.  Hepatic clearance of chemicals (e.g. hormones, drugs, and 
chemicals of exposure) relies upon several families of membrane-associated 
transport proteins working in concert with Phase-I and –II biotransformation 
enzymes.  Numerous enzymes including Cytochrome P450s, UDP-
glucuronosyl transferases (Ugts) and sulfotransferases (STs) are involved in 
biotransformation processes in liver.  The resulting glucuronide and sulfate 
metabolites typically undergo fecal and urinary excretion through bile or blood 
via transporter-dependent mechanisms localized to the canalicular or 
basolateral membrane of hepatocytes, respectively.  
Transporters are membrane proteins, which facilitate chemical transport into 
and out of cells (Klaassen and Aleksunes, 2010).  In liver, the ATP-binding 
cassette (Abc) superfamily of transporters are involved in excretion of 
endogenous and xenobiotic compounds from the body, as well as 
enterohepatic recirculation of bile acids.   Membrane transporter proteins are 
crucial in facilitating the uptake and biliary excretion of endogenous chemicals 
(e.g. conjugated hormones, bile acids, and conjugated bilirubin), and 
xenobiotics (e.g. environmental chemicals and drugs) (Faber et al., 2003).  
Changes in certain transporters can cause imbalance in endogenous 
chemicals, such as bile acids, endocrine hormones, and bilirubin (Lecureux et 
al., 2009). Moreover, xenobiotic metabolism is considered to be less efficient 
	   78 
without drug transporters (Faber et al., 2003).  Impairment of certain drug 
transporters function, such as Multidrug resistance-associated protein 2 (Mrp2, 
Abcc2) and Bile salt-export pump (Bsep, Abcb11), cause hyperbilirubinemia 
and cholestasis respectively (Faber et al., 2003).  During different pathological 
and physiological conditions, such as cholestasis or acetaminophen-induced 
liver injury, Abc transporter expression in liver is altered (Slitt et al., 2007; 
Aleksunes et al., 2008).  
Bisphenol A (BPA) is a monomer used in plastic manufacturing.  According to 
National Health and Nutrition Examination Survey, 92.6% of 2500 participants 
have BPA in urine samples (Calafat et al., 2008).  Perinatal BPA exposure to 
Avy mice disrupted sexual dimorphic gene expression and sexual trait 
expression in adult mice (Mao et al., 2010; Jasarevic et al., 2011).  In utero 
BPA exposure increased body weights in females altered mammary and 
reproductive glands, changed metabolic features, caused insulin resistance, 
increased adipogenesis, and predisposed to metabolic syndrome in pups 
(Alonso-Magdalena et al., 2006; Somm et al., 2009; Wei et al., 2011).  BPA 
exposure is emerging as a well-studied example of the “fetal basis of disease”.  
The fetal basis of adult disease hypothesis proposes that various factors, such 
as nutrition or environmental exposure during prenatal and early postnatal 
development can affect development, resulting in susceptibility to chronic 
disease as an adult (Dolinoy et al., 2007b).  Adverse effects elicited by 
developmental BPA exposure involve epigenetic mechanisms through 
modulation of DNA and histone methylation and endocrine disruption 
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(Vandenberg et al., 2009; Kundakovic and Champagne, 2011).  For example, 
BPA perinatal exposure in Avy mice changed the coat color of pups through 
epigenetic modulation via DNA hypomethylation, which was dampened by 
genestein supplementation along with BPA exposure (Dolinoy et al., 2007a).  
BPA also acts as an endocrine disruptor by mimicking estrogen and binds to 
estrogen receptors (ER, such as ER-alpha and beta. BPA is also known to act 
as a thyroid hormone antagonist (Moriyama et al., 2002).  
BPA is highly metabolized in liver and eliminated by urinary and fecal 
excretion (Pottenger et al., 2000; Volkel et al., 2002).  BPA glucuronide (BPA-
Gluc) and -sulfate (BPA-S) are the major metabolites formed in humans and 
mice (Pottenger et al., 2000; Volkel et al., 2002).  The UGT2B family and 
SULT1A1 enzymes are major biotransformation enzymes involved in BPA 
conjugation (Nishiyama et al., 2002; Hanioka et al., 2008).  In rodents, Abcc2 
is the predominant transporter, which mediates BPA-Gluc excretion from liver 
into bile (Inoue et al., 2005).  Maternal exposure to other endocrine disruptors, 
such as polybrominated diphenyls (PBDEs) and BDE47 alters expression of 
metabolic enzymes and ABC transporters (Richardson et al., 2008; Szabo et 
al., 2009). 
This study aimed to identify whether developmental BPA exposure could affect 
hepatic clearance processes, such as metabolism and disposition, in 
adulthood.  In this study two different doses of BPA were administered; 50 
µg/kg diet and 50 mg/kg diet (equivalent to 6.5 µg/kg body weight and 6.5 
mg/kg bodyweight respectively) (Rosenfeld et al., 2013).  Along with BPA 
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exposure, dams were also exposed to ethinyl estradiol as a positive control or 
co-administrated genestein with BPA as previously described (Dolinoy et al., 
2007a; Rosenfeld et al., 2013).  Overall, the results herein detail that maternal 
exposure to BPA during gestation and lactation decreased hepatic transporter 
expression in male offsprings that were 135 days or older, which was in 
association with decreased recruitment of Hdac to the Abbc2 and 3 promoter. 
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MATERIALS AND METHODS 
Animals and treatments:  All animal experiments including breeding and 
dietary exposure were conducted by Dr. Cheryl Rosenfeld’s laboratory at 
University of Missouri Columbia according to the IACUC regulations at the 
University of Missouri Columbia as previously described (Rosenfeld et al., 
2013).  Livers from this study (Rosenfeld et al., 2013) were used for the study 
herein..  Animal exposure and breeding was performed as previously 
described by Rosenfeld et al., 2013 (Rosenfeld et al., 2013).  Briefly, virgin 
females (C57Bl/6, a/a) were fed one of the following five diets 1) Corn oil 
(control), 2) BPA 50 µg/ Kg diet (low dose), 3) BPA 50mg/Kg diet (high dose), 
4) Ethniyl estradiol (EE), 0.1 µg/ Kg diet, 5) BPA 50mg/Kg and Genistein 
250mg/Kg diet (BPA-G).  Dams were fed the diet through gestation and 
lactation period.  Pups were weaned and fed control diet, such that they were 
exposed to BPA only during the period of gestation and lactation.  Livers were 
collected from male pups after postnatal day 135 days (n=5-6 per group).  
RNA Isolation and cDNA Synthesis:  Total RNA was isolated with RNAzol B 
reagent (Tel-Test Inc., Friendswood, TX).  RNA concentration was assessed 
using NanoDrop™ (UV absorbance was measured at 260 nm) and the 
integrity was confirmed by formaldehyde gel electrophoresis.  The mRNA 
samples were stored at -80°C until further use for analysis.  cDNA for each 
sample was synthesized from 1µg of total RNA using cDNA synthesis Kit 
according to the manufacturer’s protocol (Roche®, Germany). 
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qPCR Analysis:  Gene expression was analyzed using Real-time quantitative 
PCR.  qPCR was carried out using  SYBRH Green PCR Master Mix (Roche®, 
Germany) with a Light Cycler 480 II (Roche®, Germany).  Details of primers 
used were mentioned in Table 1.  
Microsomal preparation:  200mg of liver tissue (n=3-6 per group) was 
washed with ice-cold saline and 50mM sodium pyrophosphate buffer (pH-7.4).  
Following washing livers were homogenized in 600 µl homogenizing buffer 
(0.25M Sucrose, 50mM Tris-Hcl (pH-7.8), 0.5mM EDTA, 20µM BHT, 0.1mM 
DTT) and centrifuged at 10,000x g for 15 min.  The supernatant were 
centrifuged again at 100,000x g for 60 min.  The resulting cytosols were stored 
at -80°C for future use.  The microsomal pellet was re-suspended in buffer 
(0.25M Sucrose, 10mM Tris-Hcl (pH-7.8), 1mM EDTA, 20µM BHT and 20% 
glycerol) and stored at -80°C for future use. 
Enzymatic BPA Glucuronidation and analysis:  Hepatic microsomal 
fractions (0.0075mg) were incubated with 1µM BPA and 2mM UDPGA in 
50mM phosphate buffer (pH-7.0) for 30 min at 37°C.  At the end of Incubation, 
tubes were heated in boiling water to deactivate protein and centrifuged at 
14000Xg for 10 min.  Supernatant were collected and injected in to HPLC.  
BPA and BPA-Gluc were analyzed using HPLC-UV (System Gold®, Beckman 
Coulter, Inc.).  50 µl of each sample was injected onto column (ZORBAX SB-
Aq, 5µm, 4.6X150mm, Agilent Technologies).  A gradient elution used with 
80% ACN and 20% 20mM phosphate buffer (pH-2.7) at 1 ml/min flow rate 
(Wen et al., 2013) and analyzed at 200nm using an system Gold® UV detector 
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168 (Beckman Coulter, Inc).  BPA and BPA-Gluc were identified using 
standards of BPA (Sigma-Aldrich) and BPA-Gluc (Toronto research chemicals, 
Canada) made in 50mM phosphate buffer (pH-7.0).  BPA-Gluc and BPA are 
eluted at 7.4 and 10 minutes respectively.  BPA and BPA-Gluc were quantified 
by comparing area of peak with BPA and BPA-Gluc standard curves (Wen et 
al., 2013). 
Nuclear protein extraction: Nuclear extracts were isolated from liver tissue 
using Pierce NE-PER® nuclear extraction kit (Thermo Fisher Scientific, 
Rockford, IL, USA) and protein concentration was determined by the DC 
protein assay (Bio-Rad, Inc.). 
Western Blotting:  Western blots for transporters and nuclear histone 
deacetylase (Hdac), were performed according to previously published 
methods (Aleksunes et al., 2008; Donepudi et al., 2012).  50 µg nuclear, 
cytosolic, or crude membrade protein was loaded per well, and proteins were 
electrophoretically separated by a 4-20% SDS PAGE gel and transblotted onto 
PVDF membrane.  Blots were blocked with 5% non-fat dry milk in TBST.  The 
blots were incubated with primary antibody overnight, washed in TBST, and 
then incubated with secondary antibody for an hour.  Staining was visualized 
by autoradiography. Antibodies details are Abcc2 (M2III-5, Enzo Life Sciences, 
Farmingdale, NY), Abcc3 (M3II-2), Abcc4 (M4I-10), Abcg5 (BXP-53) from G. 
Scheffer laboratory (VU Medical Center, Amsterdam, The Netherlands), Bsep 
(K44), Ntcp (K4) from B. Steiger laboratory (University Hospital, Zurich, 
Switzerland), Hdac and Gadph (Cell signaling, MA, USA). 
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Transcription factor binding assay:  Nuclear extracts obtained from livers 
were quantified for transcription factor binding to a prototypical ARE 
consensus sequence using a Procarta TF 9-plex custom array (Affymetrix, 
CA) according to the manufacturer’s instructions and quantified using a Biorad 
Bioplex, which utilizes a luminex platform (Xu et al., 2012a). 
Hepatic bile acid levels:  Hepatic bile acids were extracted from using 
tertiary-butanol extraction method and quantified as described previously 
(Donepudi et al., 2012) using a bile acid assay kit (Bioquant, San Diego, CA, 
USA). 
Hepatic Glutathione levels:  Hepatic reduced glutathione (GSH) levels were 
measured using GSH-GloTM Glutathione assay kit (Promega).  Briefly, 20mg of 
liver tissue was homogenized in 2ml of 2mM EDTA in phosphate buffered 
saline (PBS) and homogenate was centrifuged.  The resulting supernatant 
was analyzed for hepatic glutathione levels.  Hepatic GSH levels were 
analyzed according to manufacturer’s protocol.  Luminescence was measured 
using a GloRunnerTM microplate luminometer interfaced with GloRunner DXL 
Software (Turner Biosystems, Sunnywale, CA, USA).  
Dibromosulfophthalein (DBSP) disposition:  DBSP (120mmole/kg/5ml, i.p.) 
was injected into mice.  Mice were euthanized 45 min after DBSP injection and 
DBSP concentration was determined in gallbladder bile.  Concentration of 
DBSP was quantified spectrophotometrically at 575 nm after alkalinization of 
the samples with 0.1M NaOH. 
Statistical Analysis: The statistical significance between groups was 
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determined using one-way ANOVA followed by a Duncan’s post hoc test, 
using Statistica 9.1 software (Stat Soft Inc., Tulsa, OK, USA).  Data are 
presented as mean ± SE, with P ≤0.05 considered statistically significant. 
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RESULTS  
Effect of developmental exposure of BPA on Body and liver weights. 
Figure 1 illustrates body and liver weights of male pups, which have 
undergone developmental exposure of BPA, EE and BPA-G.  Body weights 
were similar among BPA, EE and BPA-G developmental exposure in pups.  
Similar to body weights, exposure to the various diets did not change the liver 
weights. 
Effect of developmental exposure of BPA on Phase-II conjugation. Figure  
2A illustrates the effect of developmental BPA exposure on hepatic BPA 
glucuronidation.  In rodents, Ugt2b1 and Sul1a1 are Phase-II enzymes 
involved in BPA metabolism (Yokota et al., 1999; Nishiyama et al., 2002).  
Both BPA and EE developmental exposure decreased Ugt2b1 expression in 
pups to 35 and 31%, and Sult2a1 mRNA levels by 48 and 27 % of control diet-
exposed pups respectively.  BPA-Gluc is the predominant BPA metabolite 
formed by humans and rodents, formed through glucuronidation (Yokota et al., 
1999).  Figure 2B illustrates the effect of BPA developmental exposure on 
hepatic BPA glucronidation capacity at a relatively low BPA concentration.  
Similar to mRNA levels of Ugt2b1, BPA glucuronidation levels decreased with 
BPA developmental exposure.  BPA high dose and EE developmental 
exposure decreased BPA glucuronidation in pups to about 74% and 81% of 
control, respectively.  Genistein co-administration reversed the observed 
decrease caused by BPA developmental exposure.  The BPA concentration (1 
µm) in the reaction vessels was chosen because it is a more relevant 
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concentration and lower or as low as previously described (Wen et al., 2013).  
The observed percent decrease in BPA glucuronidation is less than the 
observed decrease in Ugt2b1 expression, and this is likely due to the low 
concentration of BPA used, which is less than Km (Mazur et al., 2010). 
Effect of developmental exposure to BPA on hepatic basolateral drug 
transporter expression.  Figure 3 illustrates effect of BPA developmental 
exposure on hepatic basolateral drug transporter expression in pups.  Hepatic 
basolateral drug transporters such as Abcc3, 4, and Ntcp expression 
decreased with BPA developmental exposure.  These observed changes were 
similar to EE exposure, whereas the effects caused by BPA developmental 
exposure were not observed with genistein exposure.  In pups, with both 
doses of BPA exposure Abcc4 and Ntcp mRNA levels decreased about to 21 
and 31 % of controls,whereas Abcc3 mRNA levels in livers of adult sons had a 
decreasing trend with BPA exposure.  Developmental exposure to EE 
decreased Abcc3, 4, and Ntcp mRNA levels about to 21, 2 and 26 %, of 
controls respectively.  Similar to mRNA levels, developmental BPA exposure 
decreased protein expression of Abcc3 and 4.  Ntcp protein expression 
decreased with both doses of BPA and increased with EE exposure compared 
to the control diet group despite decreased mRNA levels. 
Effect of developmental exposure to BPA on apical drug transporter 
expression. Figure. 4 illustrates the effect of BPA developmental exposure on 
expression of canalicular drug transporter expression in livers of adult male 
sons.  In livers of adult male sons, with both doses of BPA exposure Abcc2, 
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Abcg2, and Bsep mRNA levels were decreased to 54, 40 and 41 % of control 
diet-exposed group respectively.  EE developmental exposure decreased 
Abcc2, Abcg2, and Bsep mRNA levels about to 36, 20 and 22% of control diet 
group respectively.  Similar to mRNA levels, BPA developmental exposure 
decreased Abcc2 protein expression in liver.  Abcg2 protein expression was 
similar to controls and unaltered with BPA and EE exposure, EE exposure 
increased Bsep protein expression, whereas Bsep expression was similar 
between BPA exposed and control groups. 
Developmental BPA exposure perturbs bile acid and GSH levels in liver.  
Hepatic Abc transporters are determinants for the excretion and enterohepatic 
circulation of bile acids.  Altered hepatic Abcc2 expression was observed 
during cholestasis (Geier et al., 2003), a pathological condition caused by 
impedence of bile acids leading to bile acid accumulation in liver.  Exposure to 
the low BPA dose significantly increased hepatic bile acid concentration by 
30% compared to controls, but not at the higher BPA dose.  Abcc2 transports 
utilizes GSH as cofactor to drive biliary excretion.  Moreover Abcc2-/- mice 
have increased hepatic total glutathione levels (Chu et al., 2006).  BPA 
exposure increased GSH levels in liver by 60 and 80%, respectively, 
compared to concentrations on livers of controls (Figure 5B). 
Effect of developmental exposure of BPA on DBSP disposition.  DBSP 
disposition is used as a estimation of hepatic transport function (Dhumeaux et 
al., 1974) and targeted Abcc2 deletion significantly decreased DBSP levels in 
mice (Chu et al., 2006), illustrating DBSP as a substrate for mouse Abcc2.  
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Both BPA exposures significantly reduced DBSP levels in bile to 24 and 33%, 
of control diet group respectively (Figure 5C).  The observed decrease in 
DBSP concentration in gallbladder bile likely reflects the corresponding 
decrease in liver Abcc2 expression. 
Developmental BPA exposure decreases transcription factor expression 
and binding.  Figure 6 illustrates the effect of developmental BPA exposure 
on gene expression and binding activity of transcription factors involved in 
regulation of drug transporters and Phase-II enzymes.  In rodents, 
transcription factors such as Ahr, Car, Fxr and Nrf2 are known to regulate drug 
transporters and Phase-II enzyme expression (Rushmore and Kong, 2002; 
Nakata et al., 2006).  BPA, at both concentrations, decreased Ahr, Car, Fxr 
and Nrf2 mRNA levels in livers of adult sons by at least 41, 36, 53 and 58%, 
respectively, which was similar to EE developmental exposure.  Conversely, 
the decrease in hepatic transcription factor expression was not observed in 
livers from pups that had maternal dietary genistein supplementation.  In 
contrast to mRNA expression, transcription factor such as Ahr, Car and Fxr 
binding activity was unaltered at the lower BPA concentration fed to dams.  
However, the higher BPA dose and EE developmental exposure decreased 
Ahr, Car, and Fxr binding activity.  Both BPA exposures decreased Nrf2 
binding, which was not observed in livers from pups from dams fed BPA with 
genestein.  
Developmental BPA exposure increases Class 1 Hdac expression. In 
order to determine a mechanism by which decreased biotransformation, 
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transporter, and nuclear receptor expression occurs, it was hypothesized that 
developmental BPA exposure might affect pathways with panoramic effects of 
gene transcription.  Hdacs are known to modulate or down regulate 
expression genes such transporters.  Figure 7 illustrates Class I Hdac protein 
expression in nuclear extracts obtained from livers of adult sons from dams 
that were fed control, BPA, EE, or BPA-G diet.  Class I Hdac proteins such, as 
Hdac 1, 2 and 3, nuclear levels was increased with both doses of BPA and EE 
developmental exposure compared to control group.  Genistein co-
administration slightly increased Hdac1, 2 and 3 nuclear levels but not to the 
level of BPA and EE developmental exposure groups. 
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Discussion: 
BPA a xenoestrogen present ubiquitously in the environment (Vandenberg et 
al., 2009), and is known to cause several adverse effects (Vandenberg et al., 
2009).  BPA exposure in humans is variable as studies report different values 
of estimated human exposure (Vandenberg et al., 2009).  Toxicological 
studies identify 1000 mg BPA/kg body weight (BW)/day as maximum tolerable 
dose in humans (Vandenberg et al., 2009).  According to EPA, the daily 
tolerable intake or no observed adverse effect levels (NOAEL) of BPA is 50 
µg/kg BW/ day (Vandenberg et al., 2009).  In this study, two concentrations 
BPA were supplemented in maternal feed, one below NOAEL, one higher than 
the NOAEL.  Several studies documented, in rodent models, that BPA 
exposure is associated with physiological, behavioral and gene expression 
changes at or below NOAEL (Alonso-Magdalena et al., 2006; Somm et al., 
2009; Jasarevic et al., 2011; Wei et al., 2011; Patisaul et al., 2012), indicating 
BPA can causes several adverse effect below NOAEL. 
Despite liver being important for elimination of endocrine disrupting 
compounds and determining systemic hormone levels, few studies address 
the effect of BPA on hepatic processes like metabolism.  BPA undergoes 
extensive Phase-II conjugation, which is essential for decreasing BPA body 
burden (Volkel et al., 2002) and conjugated BPA does not have endocrine 
disruption effects caused by BPA  (Matthews et al., 2001).  BPA primarily 
undergoes glucuronidation, whereas sulfonation can occur, but is considered 
to have a minor, but appreciable role (Pottenger et al., 2000).  Species-specific 
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differences were observed in BPA elimination pathways.  In rodents, BPA-
Gluc primarily undergoes biliary excretion whereas in humans, BPA 
undergoes urinary excretion (Vandenberg et al., 2009).  In vitro studies using 
ATPase assays have identified ABCC3 in humans as a possible drug 
transporter involved in transport of BPA-Gluc (Mazur et al., 2012), whereas in 
rodents Abcc2 is major transporter of BPA-Gluc (Inoue et al., 2005). 
In the present study, the effects of developmental exposure of BPA on liver 
function and hepatic metabolic processes in adult were documented.  
Developmental BPA exposure downregulated key enzymes and transporters 
involved in BPA metabolism and excretion.  Developmental BPA exposure 
also decreased activity or function of genes involved in BPA metabolism and 
excretion.  Effects observed in this study by developmental BPA exposure are 
similar to EE developmental exposure although there were no changes in 
estrogen levels in these mice (Figure 10). BPA and EE developmental 
exposure significantly down-regulated hepatic Phase II enzymes such as 
Ugt2b1 and Sult1a1, and hepatic efflux drug transporters such as Abcc2, 3, 
and 4 expressions.  Developmental BPA and EE exposure also decreased 
BPA glucuronidation capacity of pups, which supports decrease in Phase II 
enzyme expression in liver.  Decrease in hepatic efflux transporters, primarily 
Abcc2 expression was supported by increase total hepatic glutathione levels 
and decrease of DBSP levels in bile. As mentioned previously, glutathione 
conjugates and DBSP are substrates for Abcc2 (Chu et al., 2006).  
Interestingly, changes in hepatic gene expression such Phase II enzymes and 
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Abc transporter expression due to developmental BPA exposure was reversed 
by genistein co-administration.  Serum BPA levels in dams were unaltered 
with genistein supplementation (Figure 8), indicating genistein co-
administration did not changed BPA exposure to dams and effects shown by 
genistein co-administration did not involve differences in BPA exposure. 
Decrease in hepatic metabolism genes and transcription factors by BPA 
developmental exposure in this study were supported by similar observation in 
CD-1 male pups, which are exposed to BPA at perinatal, and peripubertal 
stages (Figure 11). 
Our results shows, both doses of developmental BPA and EE exposure 
downregulated transcription factor expression such as Ahr, Car, Fxr, and Nrf2, 
and binding activity at high dose of BPA and EE developmental exposure.  
Only Nrf2 binding activity to its consensus sequence was decreased with both 
doses of BPA developmental exposure similar to Phase II and drug transporter 
expression changes caused by BPA.  This indicates Nrf2 role in BPA or EE 
induced downregulation of hepatic drug transporters and Phase II enzymes in 
pups.  Decrease in Nrf2 expression and activity was supported by decrease in 
its target gene Nqo1 expression (data not shown).   
Hepatic Ugt2b1is a key enzyme involved in conjugation of endogenous 
androgens and xenobiotics (Yokota et al., 1999).  Although Phase II enzymes 
particularly Ugt2b1 expression is minimally induced with transcription factors 
activators, Nrf2-nullmice showed significant decrease in Ugt2b1 expression 
indicating basal levels of Ugt2b1 expression is regulated by Nrf2 (Buckley and 
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Klaassen, 2009; Reisman et al., 2009).  In mice, Sult1a1 expression is 
significantly upregulated by only butylated hydroxyanisole (BHA), which is an 
activator for Nrf2.  In or study also decrease in Sult1a1 and Ugt2b1 expression 
is similar decrease in Nrf2 expression and binding activity indicating BPA 
induced downregulation of Phase II enzyme expression caused through 
repression of Nrf2 activiy. 
Studies have shown that hepatic efflux transporters such as Abcc2, 3 and 4 
expression are regulated by several transcription factors such Ahr, Car and 
Nrf2 (Maher et al., 2005).  In mice, prototypical activators of these transcription 
factors increase hepatic efflux transporter expression (Maher et al., 2005).  In 
mice, activation of Nrf2 by oxidative stress and chemical activators increased 
hepatic Abc transporters expression such as Abcc2, 3 and 4.  Moreover, 
hepatic efflux transporters such as Abcc2, 3, 4 and Abcg2 expression 
decrease significantly in Nrf2-null mice whereas there expression significantly 
increased in Keap1 knock down and Keap1 heaptocyte knockout mice 
(Reisman et al., 2009; Wu et al., 2012).  Similar to these studies, 
developmental BPA at both doses and EE exposure decreased hepatic efflux 
transporter expression and only Nrf2 expression and activity in same pattern, 
indicating Nrf2 role in BPA induced down regulation of hepatic Abcc2, 3 and 4 
transporters. 
In mice, developmental BPA exposure is known to induce epigenetic changes 
such as hypomethylation and histone modification in different tissues at 
different promoter regions (Kundakovic and Champagne, 2011). Epigenetic 
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changes specifically hypomethylation of intracisternal A particle (IAP) 
retrotransposon of agouti promoter region caused by developmental BPA 
exposure is reversed with methyl donor and genistein supplementation 
(Dolinoy et al., 2007a).  Moreover, as mentioned earlier effects observed in 
this study by BPA are similar to EE indicating these changes are caused due 
to endocrine component involved in it which is known to cause epigenetic 
changes in pups (Vandenberg et al., 2009).  In our study we observe a 
decrease in methyl cytosine levels in genomic DNA isolated from liver with 
developmental exposure of BPA although these changes are not reversed 
with genistein co-administration (Figure 9).  Apart from DNA methylation, 
histone modification such as methylation and acetylation also can regulate 
nuclear receptor inducible gene transcription (Biddie, 2011).  Hdac proteins 
are known to remodel chromatin structure and act as co-repressors for nuclear 
receptor inducible gene transcription (Biddie, 2011).  Results presented in this 
study showthat developmental BPA and EE exposure increased nuclear Hdac 
levels whereas genistein co-administration did not as much as BPA.  Increase 
in class I Hdac nuclear levels indicate decrease in nuclear receptor inducible 
gene transcription.  In vitro studies had shown role of class I Hdac proteins in 
regulation of efflux transporter expression (To et al., 2008; Xu et al., 2012b). 
Moreover studies have shown that Hdac proteins can regulate Nrf2 induced 
transcription and expression (Yu et al., 2010; Lee et al., 2012).  In accordance 
to previous studies and our results, we think developmental BPA and EE 
exposure decrease hepatic gene expression by increasing Hdac levels and 
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decreasing nuclear receptor inducible gene transcription in pups. 
Developmental BPA exposure decreases hepatic Phase II and drug 
transporter expression in pups similar to EE exposure and is reversed by 
genistein co-administration.  The observations from current study indicate 
changes in Phase II enzymes and drug transporter expression due to 
developmental BPA exposure was due caused by partly due to epigenetic 
effects such as increase in class I Hdac nuclear levels and down regulation of 
transcription factors.  Decrease in hepatic genes such as drug transporter and 
Phase II enzymes, which are involved in metabolism and elimination of 
endogenous hormones and xenobiotics can alter drug and hormonal 
metabolism.  Most importantly altered hepatic gene expression that are 
involved in metabolism due developmental BPA exposure are persistent and 
are caused below and above NOAEL, which supports BPA can cause adverse 
effects at very low doses (Vandenberg et al., 2009).  Hepatic Phase II and 
drug transporter that are altered with developmental exposure of BPA are also 
involved in hormone metabolism and elimination, changes in these gene 
expression might be responsible for endocrine disruption caused by BPA. 
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Figure Legends 
Figure 1. Effect of developmental BPA exposure on body and liver 
weights.  Both BPA and EE developmental exposure did not affect body and 
liver weights of male pups.  Data is presented as average weights (grams) ± 
S.E.M. (n=5-6 mice per group). An asterisk (*) represents a statistical 
difference between pups from control diet fed dams to pups from BPA and EE 
exposed dams (p≤0.05). 
Figure 2. Effect of developmental BPA exposure on Phase II enzymes, 
expression and activity, which are involved in BPA metabolism. Total 
RNA was isolated from livers of male pups that are developmentally exposed 
to either of diets such as control, BPA 50µg/kg and 50mg/kg, EE and BPA-G.  
(A) Hepatic phase II enzymes such as Ugt2b1 and Sult1a1 mRNA levels were 
quantified by quantitative PCR.  Data was normalized to 18S rRNA and 
presented as a mean arbitary units + S.E.M. (n=5-6 mice per group).  (B) 
Enzymatic glucuronidation activity in male pups.  Hepatic microsomes were 
isolated from frozen liver tissue.  BPA glucuronidation assays were carried out 
with 1 µM BPA and BPA glucuronide formed was analyzed using HPLC.  Data 
presented as mean BPA glucuronide formed (nmoles/mg/min) + S.E.M. (n=3-7 
mice per group).  An asterisk (*) represents a statistical difference between 
pups from control diet fed dams to pups from BPA, EE and BPA-G exposed 
dams (p≤0.05). 
Figure 3. Effect of developmental BPA exposure on hepatic basolateral 
transporter expression.  Total RNA was isolated from livers of male pups 
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that are developmentally exposed to either of diets such as control, BPA 
50µg/kg and 50mg/kg, EE and BPA-G.  (A) Hepatic basolateral transporter 
such as Abcc3, 4 and Ntcp mRNA levels were quantified by quantitative PCR.  
Data was normalized to 18S rRNA  and presented as a mean arbitary units + 
S.E.M. (n=5-6 mice per group).  An asterisk (*) represents a statistical 
difference between pups from control diet fed dams to pups from BPA, EE and 
BPA-G exposed dams (p≤0.05).  (B) Protein quantification of hepatic 
basolateral drug transporters using western blots. Data presented in order of 
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G diet and n=2 per group. 
Figure 4. Effect of developmental BPA exposure on hepatic 
apical/canalicular transporter expression. Total RNA was isolated from 
livers of male pups that are developmentally exposed to either of diets such as 
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G.  (A) Hepatic 
apical/canlicular transporter such as Abccc2, Bsep (Abcb11) and Abcg2 
mRNA levels were quantified by quantitative PCR.  Data was normalized to 
18S rRNA and presented as a mean arbitary units + S.E.M. (n=5-6 mice per 
group).  An asterisk (*) represents a statistical difference between pups from 
control diet fed dams to pups from BPA, EE and BPA-G exposed dams 
(p≤0.05).  (B) Protein quantification of hepatic basolateral drug transporters 
using western blots. Data presented in order of control, BPA 50µg/kg and 
50mg/kg, EE and BPA-G diet and n=2 per group. 
Figure 5. Effect of developmental BPA exposure on hepatic clearance.  
Changes in endogenous and xenobiotic disposition caused due to 
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developmental BPA exposure in pups. (A) Hepatic bile acid levels in male 
pups from dams exposed to BPA.  Hepatic bile acid were quantified and data 
was presented as average concentrations (µmole/l/mg) + S.E.M. (n=5-6 mice 
per group).  (B) Hepatic total glutathione levels in male pups from dams 
exposed to BPA.  Hepatic total glutathione levels were quantified and data 
was presented as average concentrations (nmole/mg) + S.E.M. (n=5-6 mice 
per group).  (C) DBSP disposition in male pups from dams exposed to BPA.  
DBSP levels in gall bladder was analyzed and data presented as 
concentration (Molar/g of gall bladder) + S.E.M. (n=3-6 mice per group).  An 
asterisk (*) represents a statistical difference between male pups from control 
diet fed dams to pups from BPA, exposed dams (p≤0.05) and (#) was 
indicated for statistical significance of p=0.06.  
Figure 6. Effect of developmental BPA exposure on transcriptional 
factors expression and binding activity.  Total RNA was isolated from livers 
of male pups that are developmentally exposed to either of diets such as 
control, BPA 50µg/kg and 50mg/kg, EE and BPA-G.  (A) Transcription factors 
such as Ahr, Car, Fxr and Nrf2 mRNA levels were quantified by quantitative 
PCR.  Data was normalized to 18S rRNA and presented as a mean arbitary 
units + S.E.M. (n=5-6 mice per group).  (B) Transcription factor binding activity 
of Ahr, Car, Fxr and Nrf2 was analyzed using TF procarta assay. Data 
presented as mean multiple fluorescence index (MFI) for n=2 samples per 
group.  An asterisk (*) represents a statistical difference between pups from 
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control diet fed dams to pups from BPA, EE and BPA-G exposed dams 
(p≤0.05). 
Figure 7. Effect of developmental exposure of BPA on nuclear levels of 
class I Hdac proteins and Hdac recruitment.  (A) Protein quantification of 
nuclear Hdac1, 2 and 3 levels was performed using western blots. Data 
presented in order of EE, control, BPA 50µg/kg and 50mg/kg, and BPA-G diet 
and n=1 per group.  Developmental BPA and EE exposure increased nuclear 
levels of class I Hdac proteins in pups.   
Figure 8. Serum BPA levels in dams exposed to different diets.  Data was 
presented as average total BPA concentration (ng/ml) ± S.E.M (n=4-6 mice 
per group).  An asterisk (*) represents a statistical difference between pups 
from control diet fed dams to pups from BPA, EE and BPA-G exposed dams 
(p≤0.05). 
Figure 9.  Effects of developmental BPA exposure on global methylation 
in male pups livers.  Total genomic DNA was isolated from livers and 
analyzed for methylated cytosine levels using methylation kits (Epigentech).  
Data was presented as average percentage of (5-methyl cytosine) ± S.E.M 
(n=5-6 mice per group). An asterisk (*) represents a statistical difference 
between pups from control diet fed dams to pups from BPA and BPA-G 
exposed dams (p≤0.05).  
Figure 10. Effects of developmental BPA exposure on serum estrogen 
levels in male pups. Serum estrogen levels are determined using serum 
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estrogen ELISA kit (Calbiotech, CA, USA).  Data was presented as average 
concentration (pg/ml) ± S.E.M (n=5-6 mice per group).   
Figure 11. Effects of developmental BPA exposure on hepatic phase II 
and drug transporter expression in male CD-1 pups. Female CD-1 mice(12 
weeks old) were bred at Tufts University Human Nutrition, Boston, MA. . On 
gestational day (GD) 6 dams were weighed and osmotic pumps (model 1004; 
Alza Corp., Palo Alto, CA, USA) with flow rate 0.11µl/hr were implanted into 
pregnant moms on GD 8 such that pups receive either vehicle (50% DMSO) or 
two BPA (25, 250 µg/kg BW/ day) treatments.  Pups are weaned and 
maintained on ad libitum diet.  Post weaning pups were exposed to similar 
BPA doses through drinking water.  Tissues from female offspring were 
collected on postnatal day 32. Total RNA was isolated from livers of male pups 
that are developmentally exposed to DMSO and BPA and mRNA levels were 
quantified by quantitative PCR.  Data was normalized to 18S rRNA and 
presented as a mean arbitary units + S.E.M. (n=9-10 mice per group).  An 
asterisk (*) represents a statistical difference between pups from control to 
pups from BPA exposed dams (p≤0.05).  
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Table 1. Detailed sequences for list of primers used in qPCR for 
quantifying gene expression 
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ABSTRACT 
Bisphenol A (BPA) is an endocrine disruptor available ubiquitously in 
environment.  BPA is exposed to humans through several forms such plastic 
bottles, canned food and even through dental sealants.  BPA is rapidly 
metabolized and excreted from body either through urine or feces.  BPA 
glucuronide (BPA-Gluc) is a major metabolite whereas BPA sulfate (BPA-S) is 
minor metabolite formed.  As BPA metabolites are termed non-toxic 
compounds, BPA metabolism has an important role in BPA induced toxicity.  
Studies have identified in humans, correlation between urinary BPA levels and 
occurrence of metabolic syndrome components such as obesity, diabetes and 
cardiovascular diseases.  Obesity is a hallmark of metabolic syndrome, which 
is a complex condition involving accumulation of fat mass and changes in 
several gene expression.  Both in humans and rodents, altered metabolism 
and disposition of xenobiotics were observed with obesity and other metabolic 
syndrome conditions.  BPA disposition during metabolic syndrome conditions 
such as obesity, fatty liver and diabetes is very less known.  In this study we 
administered BPA (10 mg/kg, i.v.) in lean and obese rats.  Bile, blood and 
urine samples were collected at different time interval and analyzed using 
UPLC-MS/MS.  Along with in vivo BPA disposition studies hepatic 
glucuronidation and sulfation enzymatic assays were performed to identify 
whether obesity altered hepatic metabolic processes.  Our results indicate 
obese rats have decreased hepatic glucuronidation and increased hepatic 
sulfation.  Changes in hepatic phase II and III protein expression in obese rats 
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resulted in altered BPA metabolism and disposition.  In obese rats BPA 
metabolites specifically BPA-Gluc levels were increased in urine and 
decreased in bile compared to lean rats.  These altered BPA metabolism and 
disposition during obesity suggests in humans, in depth evaluation of urinary 
BPA levels such as ratio of metabolite to parent compound are needed to 
correlate BPA exposure to occurrence of obesity. 
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INTRODUCTION 
BPA is a bi-product of plastic manufacturing, available ubiquitously in 
environment and exposed to humans through several forms (Vandenberg et 
al., 2009).  According National Health and Nutrition Examination Survey 
(NHANES) 92.6% of people analyzed have BPA in their urine (Calafat et al., 
2008).  Rodent studies documented, BPA can cause several adverse effects 
such as obesity, insulin resistance, oxidative stress, endocrine disruptors and 
behavioral changes (Somm et al., 2009; Vandenberg et al., 2009; Jasarevic et 
al., 2011).  BPA is highly metabolized in liver and eliminated by urinary and 
fecal excretion (Pottenger et al., 2000; Volkel et al., 2002). BPA-glucuronide 
(BPA-Gluc) and BPA-sulfate (BPA-S) are the major metabolites formed in 
humans and mice The UGT2B family and SULT enzymes are major 
biotransformation enzymes involved in BPA conjugation (Nishiyama et al., 
2002; Hanioka et al., 2008).  In rodents, Abcc2 is the predominant transporter, 
which mediates BPA-Gluc excretion from liver into bile (Inoue et al., 2005).  
Obesity is a hallmark disease of metabolic syndrome and widely considered 
as a complex condition.  Obesity is characterized by body mass index (BMI> 
30 kg/m2). There is growing concerns of obesity affecting people worldwide 
and approximately above 30% of US population was effected by obesity of 
which 5% are considered as morbidly obese (Ogden et al., 2006; Flegal et al., 
2010). The CDC estimates that more than 86% of US adults will be overweight 
and more than 50% obese by the year 2030 (Wang et al., 2008).  One of the 
major complications during obesity is NAFLD, 15-39% of US population are 
	   127 
effected by NAFLD (Younossi et al., 2002; Collantes et al., 2004). Obese 
people have altered drug absorption, distribution, metabolism and elimination 
process. Several studies documented altered metabolism and drug disposition 
in both obesity and NAFLD disease conditions (Naik et al., 2013).  During 
obesity altered pharmacokinetic parameter are related to several factors such 
as change volume of distribution, fat mass and clearance (Brill et al., 2012).  
Apart from these factors hepatic metabolism, which includes phase I, II and III 
(drug transporter) proteins also plays important role in pharmacokinetics 
aspects in obese population (Brill et al., 2012). Both in humans and rodents, 
altered phase I and, II enzymes and drug transporter expression were 
observed during NAFLD (Naik et al., 2013).  Moreover, during obesity and 
non-alcoholic fatty liver disease (NAFLD) conditions phase II enzymes and 
drug transporters involved in BPA metabolism are altered (More and Slitt, 
2011; Hardwick et al., 2013).   
There is very less known about whether changes in hepatic metabolic 
pathways in obese population alters endocrine disruptors disposition.  In this 
study we want to determine how obese population handle BPA body burden.  
In this study we also want to determine whether changes in phase II enzymes 
and drug transporters during metabolic syndrome conditions alter BPA 
metabolism and disposition.  We used lean and obese zucker rat and injected 
BPA to identify how obese population handle high amount of BPA exposure. 
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Materials and Methods: 
Animals:  Nine-week old lean and obese zucker rats (n=6) were purchased 
from Charles River Laboratories International, Inc. (MA, USA).  Rats were 
housed under a constant dark/light cycle (12 h/12 h), and given food and 
water ad libitum for 2 weeks at Department of Biomedical and Pharmaceutical 
Sciences vivarium.  Rats used for this study are 11-week old. All the animal 
experiments were conducted at the University of Rhode Island using 
procedures approved by the Institutional Care and Use Committee (IACUC). 
Surgical procedure: Both lean and obese zucker rats were anaesthetized 
using urethane (1.5 mg/kg, ip).  Left femoral vein and artery were cannulated 
using PE-50 polyethylene tubing and bile duct was cannulated using PE-10 
polyethylene tubing. Before injection of BPA femoral artery and vein cannula 
are flushed with saline.  BPA (10 mg/kg, i.v.) (Moors et al., 2006) dissolved in 
polyethylene glycol 400 and isotonic saline (20:80, w/w) was injected through 
femoral vein.  ~200 µL of blood was collected from femoral artery into 
heparanized tubes at 0, 2, 10, 20, and 40 min time interval after injection of 
BPA.  Equal amount of saline was injected through femoral vein after every 
blood collection.  Bile samples were collected at 0, 15, 30, 45 and 60 min time 
intervals after BPA administration.  At the end of 90 min, urine was collected 
using 3 mL syringe and 22-gauge needle by puncturing bladder (Lickteig et al., 
2007).  At the end rats were euthanized and liver were collected and snap 
frozen in liquid nitrogen.  All samples collected were stored in -80°C until 
analysis. 
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Microsomes preparation:  200mg of liver tissue (n=3-6 per group) was 
washed with ice-cold saline and 50mM sodium pyrophosphate buffer (pH-7.4).  
Following washing livers were homogenized in 600 ml homogenizing buffer 
(0.25M Sucrose, 50mM Tris-Hcl (pH-7.8), 0.5mM EDTA, 20mM BHT, 0.1mM 
DTT) and centrifuged at 10,000x g for 15 min.  Supernates were centrifuged 
again at 100,000x g for 60 min.  Cytosolic supernate was transferred to tube 
and stored at -80°C for future use.  Microsomal pellet was re-suspended in re-
suspending buffer (0.25M Sucrose, 10mM Tris-Hcl (pH-7.8), 1mM EDTA, 
20mM BHT and 20% glycerol) and stored at -80°C for future use. 
Enzymatic Glucuronidation and analysis:  Hepatic microsomal fractions 
(0.0075 mg) were incubated with 1µM BPA and 2mM UDPGA in 50mM 
phosphate buffer (pH-7.0) for 30 min at 37°C.  At the end of Incubation, tubes 
were heated in boiling water to deactivate protein and centrifuged at 14000Xg 
for 10 min.  Supernatant were collected and 50 µL of each sample injected in 
to HPLC-UV (System Gold®, Beckman Coulter, Inc.).  BPA and BPA-Gluc 
were analyzed with a gradient elution, 80% ACN and 20% 20mM phosphate 
Buffer (pH-2.7) at 1 mL/min flow rate using ZORBAX SB-Aq column (5µm, 
4.6X150mm, Agilent Technologies) (Wen et al., 2013).  BPA and BPA-Gluc 
were identified using standards of BPA (sigma-aldrich) and BPA-Gluc (Toronto 
research chemicals, Canada) made in 50 mM phosphate buffer (pH-7.0). BPA-
Gluc and BPA are eluted at 7.4 and 10 minutes respectively.  BPA and BPA-
Gluc were quantified by comparing area of peak with standards. 
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Enzymatic Sulfation and analysis: The cytosolic fraction were incubated 
with 2.4 µM of radiolabeled sulfonyl donor [35S]-3'-phosphoadenosine-5'-
phosphosulfate (35S-PAPS) and 4 µM BPA in 20 mM potassium phosphate 
(pH-7.0).  The reaction mixture was incubated for a 60 min at 37ºC, after 
incubation protein reaction was stopped by heating in boiling water for 30 sec, 
and centrifuged at 14,000 x g for 20 min to pellet the protein.  For separation 
of reaction components, the resulting supernate was injected onto 
phenomenex synergi polar-RP column (50 x 2.00 mm, 4 micron).  A linear 
gradient of 15-80% acetonitrile and 20 mM potassium phosphate (pH-2.7) in 8 
min was used as mobile phase to separate excess 35S-PAPS from BPA-35S.  
35S-labeled peaks were quantified on a flow scintillation analyzer (Packard 
Bioscience, 500 TR series) with Perkin-Elmer Ultima Flo-M scintillation 
cocktail.  35S-PAPS was eluted with the solvent front and BPA-35S at 4.8 min. 
Sample preparation and detection: BPA and BPA metabolites were 
detected using sold phase extraction followed by UPLC-MS/MS. Method used 
in this study is a modified version of previously published study by Coughlin et 
al., 2011.  Brefily, 100 µL of plasma, bile and urine samples were diluted to 1 
mL with dilution buffer (Citrate, 100 µL of 250 mM ammoniumacetate (pH 5), 
80 µL of 1 M formic acid, and water) and extracted using Bond Elut Plexa 
cartridges (Varian Inc., Palo Alto, CA, USA; 60 mg, 1 mL).  BPA and its 
metabolites are eluted in 8mL of elution solution (ethanol, methanol and 
acetonitrile).  Eluted solution is evaporated and extract was reconstituted in 
200 µL 75% acetonitrile in water.  10 µL of reconstituted sample was injected 
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into UPLC MS/MS, BPA and its metabolites were quantified by comparing 
standards (Coughlin et al., 2011).  In this study data represented from bile and 
urine sample have n= 6 samples per group whereas plasma samples are n= 
5-6 per group. 
Statistical Analysis: The statistical significance between groups was 
determined using one-tailed student t-test.  Data are presented as mean ± SE, 
with P ≤0.05 considered statistically significant. 
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Results: 
Enzymatic BPA glucuronidation and Sulfation:  Figure 1 illustrates hepatic 
glucuronidation and sulfation in both lean and obese rats.  Hepatic 
glucuronidtation was significantly reduced in obese rats compared to leans by 
42% (Figure 1A).  In Vitro sulfation assay showed 1.4-fold increase in hepatic 
sulfation in obese zucker rats compared to lean zucker rats (Figure 1B).   
Effect of obesity on BPA and its metabolite disposition:  Cumulative 
biliary excretion of BPA and its metabolites are shown in figure 2.  Obese 
zucker rats have increased biliary excretion of BPA compared to leans (figure 
2A).  In obese rats, 21.82 µg/mL of cumulative amount of BPA excreted into 
bile whereas lean rats have 7.85 µg/mL indicating 3-fold increase of BPA in 
bile.  BPA levels in bile are significantly higher at all time points in obese 
zucker rats compared to lean rats.  BPA-Gluc is a major metabolite 
quantitatively excreted into bile.  In obese zucker rats BPA-Gluc excretion into 
bile was significantly decreased compared to lean rats.  Significant differences 
in BPA-Gluc levels in bile was observed at initial time points such as 15, 30 
and 45 min.  These significant differences in BPA-Gluc levels were diminished 
at later time pioints.  Biliary excretion of BPA-S was decreased in obese 
compared to lean rats (figure 2C).  Decrease in BPA-S biliary levels in obese 
rats was observed at all time points. 
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Figure 3 shows cumulative levels of BPA and its metabolites in plasma.  
Cumulative plasma BPA levels did not altered in obese rats compared to lean 
rats.  Cumulative BPA-Gluc levels in plasma showed an increasing trend in 
obese compared to lean rats (figure 3B).  Cumulative BPA-S levels in plasma 
were unaltered in obese rats (figure 3C).  Figure 4 shows cumulative levels of 
BPA and its metabolites in urine. Interestingly, although no significant changes 
were observed with plasma BPA-Gluc and BPA-S levels urine BPA-Gluc and 
BPA-S levels increased significantly.  
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Discussion: 
Etiology of obesity and metabolic syndrome includes several factors like diet, 
decreased physical activity, genetics and environmental chemicals (Heindel 
and vom Saal, 2009).  Rodent studies identified several environmental 
chemical and drug molecules that can cause obesity and NAFLD (Heindel and 
vom Saal, 2009).  Environmental chemicals that cause obesity are termed as 
obesogens (Heindel and vom Saal, 2009).  Several studies have correlated 
urinary BPA levels in humans with altered kidney function and several 
condition of metabolic syndrome such as diabetes, cardiovascular and obesity 
(Lang et al., 2008; Melzer et al., 2010; Trasande et al., 2012; Trasande et al., 
2013). Rodent studies identified both developmental and daily BPA exposure 
causes obesity and hepatic steatosis, a benign condition of NAFLD (Somm et 
al., 2009; Marmugi et al., 2012).  As BPA exposure and occurrence of obesity 
are interlinked to each other, in this study we showed how changes in phase II 
and drug transporter expression during obesity alters BPA body burden. 
Obese zucker rats have spontaneous mutation in fa gene (leptin receptor) 
present in chromosome 13 (Kanasaki and Koya, 2011).  Obese zucker rats 
displayed hyperglycemia, hypelipidemia and hyperinsulinemia conditions and 
these rats are used as a rodent models for obesity, diabetes and NAFLD 
disease conditions (Kanasaki and Koya, 2011).  As mentioned previously 
obesity and NAFLD disease condition have altered pharmacokinetics of drug 
substances in both human and rodents.  Similar to obese patients, obese 
zucker rats displayed altered acetaminophen disposition and have decrease in 
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acetaminophen-induced toxicity (Blouin et al., 1987; Lickteig et al., 2007; 
Hardwick et al., 2013).  Obese Zucker rats also displayed altered phase II 
enzyme and drug transporters expression.  In this study we used obese 
zucker rats as a model to identify whether change in metabolism gene 
expression during obesity alters BPA disposition. 
BPA majorly undergo extensive metabolism BPA-Gluc is a major metabolite 
formed whereas BPA-S is minor metabolite.  In both humans and rodents BPA 
is metabolized extensively in liver and intestines (Pottenger et al., 2000; Volkel 
et al., 2002).  In rodents, Ugt2b1 is a liver specific enzyme, which is 
predominantly involved in hepatic glucuronidation of BPA (Yokota et al., 
1999).  Studies have documented hepatic Ugt2b1 expression decreased in 
obese zucker compared to lean (Kim et al., 2004).  Decrease in observed 
hepatic glucuronidation capacity in obese zucker rats is due to decrease in 
Ugt2b1 expression.  In humans, BPA is metabolized by several UGT isoforms 
such as 2B15, 2B7, 1A8 and 1A9 (Hanioka et al., 2008).  Among these 
isoforms UGT2B15 was considered to be major isoform involved in hepatic 
BPA glucuronidation (Hanioka et al., 2008).  Interestingly in humans UGT 
isoforms expression involved in BPA metabolism were not altered with 
development of NAFLD, indicating BPA glucurondation may not be altered 
during obesity and NAFLD (Hardwick et al., 2013).  Studies identified 
expression of certain UGT isoforms may not translate to their activity (Court, 
2010).  Lorazepam, and oxazepam, substrates for UGT2B15 were 
metabolized more in obese patients (Abernethy et al., 1983) whereas UGT2B7 
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substrate mycophenolic acid conjugation was decreased during diabetes 
(Dostalek et al., 2011).  These changes indicate altered metabolism especially 
hepatic BPA glucuronidation during obesity, diabetes and NAFLD, which are 
components of metabolic syndrome.  
Both in humans and rodents BPA sulfation is a minor pathway, which is 
catalyzed by SULT1A1 predominantly (Nishiyama et al., 2002).  In rodents, 
diet induced obesity increased Sult1a1 expression, which is similar to 
SULT1A1 expression in human steatotic livers (Hardwick et al., 2013).  
SULT1A1 is involved in sulfation of phenolic compounds like acetaminophen.  
Studies have documented during NAFLD both in human and rodents 
acetaminophen sulfation increased (Lickteig et al., 2007; Hardwick et al., 
2013).  This indicates both humans and rodents have increased BPA sulfate 
formation during obesity. 
In humans BPA is rapidly metabolized and excreted through urine whereas, in 
rodents BPA metabolites are excreted through feces (Volkel et al., 2002).  
Transporters involved in BPA metabolites excretion are different in human and 
in rodents (Mazur et al., 2012).  BPA-Gluc, a major metabolite formed in BPA 
metabolism is transported by Abcc2 in rodents (Inoue et al., 2005).  
Transporter assays using membrane ATPase assays identified in humans 
ABCC3 might be involved in BPA-Gluc transport (Mazur et al., 2012). ABCC3 
is efflux drug transporter present on basolateral membrane of hepatocyte and 
inovolved in excretion of endogenous and xenobiotics from liver into blood 
(Klaassen and Aleksunes, 2010). In obese zucker rats hepatic Abcc2 
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expression was significantly downregulated (Geier et al., 2005).  Decrease in 
hepatic phase II and III (drug transporter) expression in obese rats play major 
role in altered disposition of BPA.  Decrease cumulative BPA-Gluc levels in 
bile is may be due to decreased Abcc2 expression.  Studies have documented 
that rats lacking Abcc2 show decreased BPA-Gluc biliary excretion (Inoue et 
al., 2005).  Decreased biliary BPA-Gluc excretion resulted in increase of 
plasma and urine cumulative BPA-Gluc levels. 
Changes in humans, during NAFLD hepatic altered phase II and III protein 
expression was observed (Hardwick et al., 2011; More and Slitt, 2011; 
Hardwick et al., 2013).  As mentioned previously, in humans during obesity 
increased glucuronide conjugate formation of lorazepam, and oxazepam was 
observed, which are substrates for UGT2B15 (Abernethy et al., 1983).  
Increase in UGT2B15 activity in obese people indicates that obese patient can 
detoxify BPA more efficiently than normal population.  Moreover in humans, 
hepatic ABCC3 expression increased with increase in progression of NAFLD 
(Hardwick et al., 2011; More and Slitt, 2011).  This indicates obese people will 
have high clearance of BPA-Gluc from liver, which ultimately results in 
increased BPA-Gluc urinary excretion.   
As mentioned previously, in humans urinary BPA levels are correlated with 
obesity.  In most of these studies only total urinary BPA levels were observed 
and these studies did not specified ratio of BPA and its metabolites in human 
urine samples (Carwile and Michels, 2011; Trasande et al., 2012; Wang et al., 
2012).  May be high amount of total BPA in obese human urine may be result 
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of altered metabolism and disposition of BPA.  Correlation between obesity 
and urinary BPA levels observed from previous studies may need more 
evaluation.  Detailed evaluation of BPA and its metabolites in human urine 
gives more information whether obesity and BPA exposure are interlinked in 
humans or not.   
In conclusion, hepatic clearance plays a major role in detoxifying and 
elimination of BPA from body.  We think changes in phase II and III protein 
during obesity will alter hepatic clearance of BPA and its metabolites.  Our 
model of obesity in which altered hepatic phase II and III protein expression 
resulted in altered BPA metabolism and disposition.  Although our model did 
not show same changes that are observed in obese human population, it 
strongly indicates that BPA metabolism and disposition will be altered during 
obesity.  In humans, correlation between total BPA levels in urine cannot be 
correlated to obesity, as obese population is known to have altered ADME.  In 
depth evaluation of BPA levels such as ratio of metabolite to parent compound 
are needed to correlate BPA exposure to occurrence of obesity. 
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Figure Legends: 
Figure 1. Altered hepatic BPA glucuronidation and sulfation due to 
obesity.  A) BPA hepatic glucuronidation was decreased in obese zucker rats.  
Hepatic microsomes are incubated with 1 µM of BPA and 1mM of UDPGA for 
30 min at 37°C.  Amount of BPA-Gluc formed was measured using HPLC-UV 
and data represented as average BPA-Gluc formed (nmol/min/mg) ± S.E.M 
(n=6 per group).  B) BPA hepatic sulfation was increased in obese zucker rats.  
Hepatic cytosolic fractions were incubated with 4 µM BPA and 2.4 µM 35S-
PAPS for 1 hour at 37 °C.  Amount of BPA-35S formed was analyzed using 
HPLC attached to scintillation counter detector and data represented as 
average BPA-35S formed (pmol/min/mg) ± S.E.M (n=6 per group).  Asterisk (*) 
represents statistical significance between lean and obese zucker rats 
(p<0.05). 
Figure 2. Altered hepatic BPA and BPA metabolites disposition in bile 
due to obesity.  Cumulative biliary excretion of BPA (A), BPA-Gluc (B) and 
BPA-S (C) in both lean and obese zucker rats following BPA administration.  
Both lean and obese zucker femoral artery and, vein, and bile duct were 
cannulated.  BPA (10mg/kg) administered through femoral vein and bile 
samples were collected at 15, 30, 45, 60 and 90 min time intervals. BPA and 
BPA metabolites were analyzed using UPLC-MS/MS technique. Asterisk (*) 
represents statistical significance between lean and obese zucker rats 
(p<0.05). 
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Figure 3. Altered hepatic BPA and BPA metabolites disposition in 
plasma due to obesity. Cumulative plasma levels of BPA (A), BPA-Gluc (B) 
and BPA-S (C) in both lean and obese zucker rats following BPA 
administration.  Both lean and obese zucker femoral artery and, vein, and bile 
duct were cannulated.  BPA (10mg/kg) administered through femoral vein and 
blood samples were collected at 2, 10, 20, 40 and 60 min time intervals. BPA 
and BPA metabolites were analyzed using UPLC-MS/MS technique. Asterisk 
(*) represents statistical significance between lean and obese zucker rats 
(p<0.05). 
Figure 4. Altered hepatic BPA and BPA metabolites disposition in urine 
due to obesity. Cumulative urinary excretion of BPA (A), BPA-Gluc (B) and 
BPA-S (C) in both lean and obese zucker rats following BPA administration.  
Both lean and obese zucker femoral artery and, vein, and bile duct were 
cannulated.  BPA (10mg/kg) administered through femoral vein and urine 
samples were collected at 30, 60 and 90 min time intervals. BPA and BPA 
metabolites were analyzed using UPLC-MS/MS technique.  Data represented 
as averageof BPA or its metabolites (ng/mL) ± S.E.M (n=6 per group).  
Asterisk (*) represents statistical significance between lean and obese zucker 
rats (p<0.05). 
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Conclusion 
In conclusion, we observed Abc drug transporter expression was altered with 
obesity, age and maternal diet.  Changes in Abc drug transporters can alter 
hepatic clearance and endocrine disruptor disposition.  Abc drug transporters 
expression was not only regulated by transcription factors but also with 
epigenetic mechanisms and serum metabolism-related hormones, which are 
involved with glucose and lipid metabolism.  Detailed conclusions for each study 
are below: 
In first study we observed ontogeny of drug transporters and physiological factors 
during development of obesity are sex specific.  Sex-specific correlations were 
observed between physiological factors and gene expression.  Sex-specific 
differences in correlations and expression of genes are may be due to regulation 
of hepatic drug transporters with endocrine hormones such as androgens, 
estrogen and growth hormones, which are known to be different in both male and 
females. Correlations between gene expression and physiological factors 
indicate serum hormone may have a role in regulation in drug transporters during 
development of obesity.  In males, high correlations with serum resistin and 
glucagon with hepatic Abc transporter expression indicates serum resistin and 
glucagon can be a possible biomarker for change in Abc drug transporter 
expression during development of obesity.  
Second study illustrated that maternal diet can regulate hepatic gene expression.  
In male pups, BPA developmental exposure decreased key hepatic Abc drug 
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transporters, which are involved in efflux of xenobiotics and endogenous 
hormone conjugates from liver. Observed developmental BPA exposure effects 
are similar to estrogen developmental exposure effects.  BPA and estradiol 
development exposure also decreased transcription expression and activity, 
which were involved in regulation of Abc expression in liver.  Phytoestrogen such 
as genistein supplementation in maternal diet along with developmental BPA 
exposure reversed changes observed with BPA exposure.  Global decrease in 
hepatic Abc drug transporters, Phase II enzyme and transcription factor 
expression and activity caused by BPA and estradiol involves epigenetic effects.  
Both BPA and estradiol developmental exposures increased histone 
deacetylases (Hdacs) expression whereas genistein co-administration decreased 
Hdacs, which are involved in down regulation of gene expression by epigenetic 
mechanisms. 
In third study we observed altered dispositon of BPA during obesity.  Changes in 
hepatic Phase II enzymes and Abc drug transpoters are reflected in changes in 
BPA disposition.  Specifically, decrease in hepatic UDP-glucuronosyl 
transferases 2b1 (Ugt2b1) in obese Zucker rats resulted in decrease in BPA 
glucuronidation in obese rats.  Decrease in BPA glucuronidation, which is a 
major pathway for detoxification of BPA, increases body burden of BPA in obese 
rats.  Decrease in hepatic Abcc2 expression obese rats resulted decrease in 
BPA-glucuronide (BPA-gluc) levels in bile which eventually resulted in increase 
of BPA-gluc levels in plasma and urine. Increase of hepatic sulfonation in obese 
rats caused increase in BPA-S levels in urine, although BPA-S decreased in bile. 
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These results supports that altered Phase II and Abc drug transporter expression 
in liver during obesity will results in altered disposition of endocrine disruptors 
and increases body burden of BPA. 
 
